Breast Cancer

Overview

Literature Analysis

Mouse over the terms for more detail; many indicate links which you can click for dedicated pages about the topic.

Tag cloud generated 10 March, 2017 using data from PubMed, MeSH and CancerIndex

Mutated Genes and Abnormal Protein Expression (1150)

How to use this data tableClicking on the Gene or Topic will take you to a separate more detailed page. Sort this list by clicking on a column heading e.g. 'Gene' or 'Topic'.

GeneLocationAliasesNotesTopicPapers
BRCA2 13q13.1 FAD, FACD, FAD1, GLM3, BRCC2, FANCD, PNCA2, FANCD1, XRCC11, BROVCA2 -BRCA2 and Breast Cancer
-Prophylactic Treatments for Women with BRCA1/BRAC2 mutations
-BRCA2 and Breast Cancer During Pregnancy
-BRCA2 and Outcome in Breast Cancer
3000
BRCA1 17q21.31 IRIS, PSCP, BRCAI, BRCC1, FANCS, PNCA4, RNF53, BROVCA1, PPP1R53 Germline
-185delAG mutation (c.68_69delAG) in BRCA1
-Prophylactic Treatments for Women with BRCA1/BRAC2 mutations
-BRCA1 mutations in Breast Cancer
3000
MKI67 10q26.2 KIA, MIB-, MIB-1, PPP1R105 -MKI67 and Breast Cancer
1780
TP53 17p13.1 P53, BCC7, LFS1, TRP53 -TP53 mutations in Breast Cancer
1606
BCR 22q11.23 ALL, CML, PHL, BCR1, D22S11, D22S662 -BCR and Breast Cancer
901
ERBB2 17q12 NEU, NGL, HER2, TKR1, CD340, HER-2, MLN 19, HER-2/neu Gene Amplification
-HER2 and Breast Cancer
815
PTEN 10q23.31 BZS, DEC, CWS1, GLM2, MHAM, TEP1, MMAC1, PTEN1, 10q23del -PTEN and Breast Cancer
535
NODAL 10q22.1 HTX5 -NODAL and Breast Cancer
491
MUC1 1q21 EMA, MCD, PEM, PUM, KL-6, MAM6, MCKD, PEMT, CD227, H23AG, MCKD1, MUC-1, ADMCKD, ADMCKD1, CA 15-3, MUC-1/X, MUC1/ZD, MUC-1/SEC Prognostic
-MUC1 Expression in Breast Cancer
465
CYP19A1 15q21.1 ARO, ARO1, CPV1, CYAR, CYP19, CYPXIX, P-450AROM -CYP19A1 and Breast Cancer
458
AKT1 14q32.32 AKT, PKB, RAC, CWS6, PRKBA, PKB-ALPHA, RAC-ALPHA -AKT1 and Breast Cancer
344
PROC 2q13-q14 PC, APC, PROC1, THPH3, THPH4 -PROC and Breast Cancer
342
CTNNB1 3p22.1 CTNNB, MRD19, armadillo -CTNNB1 and Breast Cancer
332
AR Xq12 KD, AIS, AR8, TFM, DHTR, SBMA, HYSP1, NR3C4, SMAX1, HUMARA -AR and Breast Cancer
322
CD44 11p13 IN, LHR, MC56, MDU2, MDU3, MIC4, Pgp1, CDW44, CSPG8, HCELL, HUTCH-I, ECMR-III -CD44 and Breast Cancer
320
KITLG 12q22 SF, MGF, SCF, FPH2, FPHH, KL-1, Kitl, SHEP7 -KITLG and Breast Cancer
304
ABCB1 7q21.12 CLCS, MDR1, P-GP, PGY1, ABC20, CD243, GP170 -ABCB1 and Breast Cancer
304
CHEK2 22q12.1 CDS1, CHK2, LFS2, RAD53, hCds1, HuCds1, PP1425 -CHEK2 and Breast Cancer
300
SRC 20q12-q13 ASV, SRC1, c-SRC, p60-Src -SRC and Breast Cancer
298
BIRC5 17q25 API4, EPR-1 -BIRC5 and Breast Cancer
288
CDKN2A 9p21.3 ARF, MLM, P14, P16, P19, CMM2, INK4, MTS1, TP16, CDK4I, CDKN2, INK4A, MTS-1, P14ARF, P19ARF, P16INK4, P16INK4A, P16-INK4A -CDKN2A and Breast Cancer
271
BAX 19q13.33 BCL2L4 -BAX and Breast Cancer
270
CCND1 11q13.3 BCL1, PRAD1, U21B31, D11S287E -CCND1 and Breast Cancer
268
CDKN1A 6p21.2 P21, CIP1, SDI1, WAF1, CAP20, CDKN1, MDA-6, p21CIP1 -CDKN1A and Breast Cancer
263
ESR1 6q25.1 ER, ESR, Era, ESRA, ESTRR, NR3A1 -ESR1 and Breast Cancer
258
MYC 8q24.21 MRTL, MYCC, c-Myc, bHLHe39 -MYC and Breast Cancer
248
PTGS2 1q25.2-q25.3 COX2, COX-2, PHS-2, PGG/HS, PGHS-2, hCox-2, GRIPGHS -PTGS2 (COX2) and Breast Cancer
-COX2 Inhibitors for Breast Cancer
150
ATM 11q22.3 AT1, ATA, ATC, ATD, ATE, ATDC, TEL1, TELO1 -ATM and Breast Cancer
232
TNF 6p21.3 DIF, TNFA, TNFSF2, TNF-alpha -TNF and Breast Cancer
232
PIK3CA 3q26.3 MCM, CWS5, MCAP, PI3K, CLOVE, MCMTC, p110-alpha -PIK3CA and Breast Cancer
228
MTOR 1p36.2 FRAP, FRAP1, FRAP2, RAFT1, RAPT1 -MTOR and Breast Cancer
218
GSTP1 11q13.2 PI, DFN7, GST3, GSTP, FAEES3, HEL-S-22 -GSTP1 and Breast Cancer
214
RAD51 15q15.1 RECA, BRCC5, FANCR, MRMV2, HRAD51, RAD51A, HsRad51, HsT16930 -RAD51 and Breast Cancer
208
TOP1 20q12-q13.1 TOPI -TOP1 and Breast Cancer
207
MET 7q31 HGFR, AUTS9, RCCP2, c-Met -C-MET and Triple Negative Breast Cancer
-C-MET and Breast Cancer
-Proto-Oncogene Proteins c-met and Triple Negative Breast Cancer
186
CYP2D6 22q13.1 CPD6, CYP2D, CYP2DL1, CYPIID6, P450C2D, P450DB1, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, P450-DB1 -CYP2D6 and Breast Cancer
196
CDH1 16q22.1 UVO, CDHE, ECAD, LCAM, Arc-1, CD324 -CDH1 and Breast Cancer
174
CYP1A1 15q24.1 AHH, AHRR, CP11, CYP1, P1-450, P450-C, P450DX -CYP1A1 and Breast Cancer
171
MDM2 12q14.3-q15 HDMX, hdm2, ACTFS -MDM2 and Breast Cancer
170
KLK3 19q13.41 APS, PSA, hK3, KLK2A1 -PSA expression in Breast Cancer
169
FGFR2 10q26 BEK, JWS, BBDS, CEK3, CFD1, ECT1, KGFR, TK14, TK25, BFR-1, CD332, K-SAM -FGFR2 and Breast Cancer
161
CDKN1B 12p13.1-p12 KIP1, MEN4, CDKN4, MEN1B, P27KIP1 Prognostic
-CDKN1B and Breast Cancer
158
GSTM1 1p13.3 MU, H-B, GST1, GTH4, GTM1, MU-1, GSTM1-1, GSTM1a-1a, GSTM1b-1b -GSTM1 and Breast Cancer
152
PPARG 3p25 GLM1, CIMT1, NR1C3, PPARG1, PPARG2, PPARgamma -PPARG and Breast Cancer
151
HIF1A 14q23.2 HIF1, MOP1, PASD8, HIF-1A, bHLHe78, HIF-1alpha, HIF1-ALPHA -HIF1A and Breast Cancer
150
MMP2 16q12.2 CLG4, MONA, CLG4A, MMP-2, TBE-1, MMP-II -MMP2 and Breast Cancer
146
TIMP1 Xp11.3-p11.23 EPA, EPO, HCI, CLGI, TIMP -TIMP1 and Breast Cancer
145
FOS 14q24.3 p55, AP-1, C-FOS -FOS and Breast Cancer
145
TFF1 21q22.3 pS2, BCEI, HPS2, HP1.A, pNR-2, D21S21 -TFF1 and Breast Cancer
142
STAT3 17q21.31 APRF, HIES, ADMIO -STAT3 and Breast Cancer
140
CD24 6q21 CD24A -CD24 and Breast Cancer
136
CXCR4 2q21 FB22, HM89, LAP3, LCR1, NPYR, WHIM, CD184, LAP-3, LESTR, NPY3R, NPYRL, WHIMS, HSY3RR, NPYY3R, D2S201E -CXCR4 and Breast Cancer
129
BCL2 18q21.3 Bcl-2, PPP1R50 -BCL2 and Breast Cancer
128
VEGFA 6p12 VPF, VEGF, MVCD1 -VEGFA and Breast Cancer
127
CYP1B1 2p22.2 CP1B, GLC3A, CYPIB1, P4501B1 -CYP1B1 and Breast Cancer
126
BLID 11q24.1 BRCC2 -BLID and Breast Cancer
124
TGFB1 19q13.1 CED, LAP, DPD1, TGFB, TGFbeta -TGFB1 and Breast Cancer
123
IGF1R 15q26.3 IGFR, CD221, IGFIR, JTK13 -IGF1R and Breast Cancer
120
CASP8 2q33-q34 CAP4, MACH, MCH5, FLICE, ALPS2B, Casp-8 -CASP8 and Breast Cancer
119
CAMP 3p21.3 LL37, CAP18, CRAMP, HSD26, CAP-18, FALL39, FALL-39 -CAMP and Breast Cancer
116
COMT 22q11.21 HEL-S-98n -COMT and Breast Cancer
115
CISH 3p21.3 CIS, G18, SOCS, CIS-1, BACTS2 -CISH and Breast Cancer
112
PCNA 20pter-p12 ATLD2 -PCNA and Breast Cancer
111
GSTT1 22q11.23 -GSTT1 Polymorphisms and Breast Cancer
109
TOP2A 17q21-q22 TOP2, TP2A -TOP2A and Breast Cancer
108
FLCN 17p11.2 BHD, FLCL -FLCN and Breast Cancer
107
XRCC1 19q13.2 RCC -XRCC1 and Breast Cancer
107
BARD1 2q35 -BARD1 and Breast Cancer
106
PARP1 1q41-q42 PARP, PPOL, ADPRT, ARTD1, ADPRT1, PARP-1, ADPRT 1, pADPRT-1 -PARP1 and Breast Cancer
100
NOTCH1 9q34.3 hN1, AOS5, TAN1, AOVD1 -NOTCH1 and Breast Cancer
99
BAD 11q13.1 BBC2, BCL2L8 -BAD and Breast Cancer
99
CXCL12 10q11.1 IRH, PBSF, SDF1, TLSF, TPAR1, SCYB12 -CXCL12 and Breast Cancer
91
CYP17A1 10q24.3 CPT7, CYP17, S17AH, P450C17 -CYP17A1 and Breast Cancer
90
ETS1 11q24.3 p54, ETS-1, EWSR2, c-ets-1 -ETS1 and Breast Cancer
87
RASSF1 3p21.3 123F2, RDA32, NORE2A, RASSF1A, REH3P21 -RASSF1 and Breast Cancer
86
ABCG2 4q22 MRX, MXR, ABCP, BCRP, BMDP, MXR1, ABC15, BCRP1, CD338, GOUT1, CDw338, UAQTL1, EST157481 -ABCG2 and Breast Cancer
86
CDK2 12q13 CDKN2, p33(CDK2) -CDK2 and Breast Cancer
86
TGFBR1 9q22 AAT5, ALK5, ESS1, LDS1, MSSE, SKR4, ALK-5, LDS1A, LDS2A, TGFR-1, ACVRLK4, tbetaR-I -TGFBR1 and Breast Cancer
85
FOXA1 14q21.1 HNF3A, TCF3A -FOXA1 and Breast Cancer
85
CDK4 12q14 CMM3, PSK-J3 -CDK4 and Breast Cancer
84
GATA3 10p15 HDR, HDRS -GATA3 and Breast Cancer
80
E2F1 20q11.2 RBP3, E2F-1, RBAP1, RBBP3 -E2F1 and Breast Cancer
78
NME1 17q21.3 NB, AWD, NBS, GAAD, NDKA, NM23, NDPKA, NDPK-A, NM23-H1 -NME1 and Breast Cancer
77
CYP3A4 7q21.1 HLP, CP33, CP34, CYP3A, NF-25, CYP3A3, P450C3, CYPIIIA3, CYPIIIA4, P450PCN1 -CYP3A4 and Breast Cancer
76
ERBB3 12q13 HER3, LCCS2, ErbB-3, c-erbB3, erbB3-S, MDA-BF-1, c-erbB-3, p180-ErbB3, p45-sErbB3, p85-sErbB3 -ERBB3 and Breast Cancer
76
SMAD3 15q22.33 LDS3, LDS1C, MADH3, JV15-2, HSPC193, HsT17436 -SMAD3 and Breast Cancer
75
SERPINE1 7q22.1 PAI, PAI1, PAI-1, PLANH1 -SERPINE1 and Breast Cancer
73
SULT1A1 16p12.1 PST, STP, STP1, P-PST, ST1A1, ST1A3, TSPST1, HAST1/HAST2 -SULT1A1 and Breast Cancer
73
XRCC3 14q32.3 CMM6 -XRCC3 and Breast Cancer
72
JUN 1p32-p31 AP1, AP-1, c-Jun -c-Jun and Breast Cancer
72
TERT 5p15.33 TP2, TRT, CMM9, EST2, TCS1, hTRT, DKCA2, DKCB4, hEST2, PFBMFT1 -TERT and Breast Cancer
72
RHOC 1p13.1 H9, ARH9, ARHC, RHOH9 -RHOC and Breast Cancer
72
MIR21 17q23.1 MIRN21, miR-21, miRNA21, hsa-mir-21 -MicroRNA miR-21 and Breast Cancer
71
CEACAM5 19q13.2 CEA, CD66e -CEACAM5 and Breast Cancer
71
RB1 13q14.2 RB, pRb, OSRC, pp110, p105-Rb, PPP1R130 -RB1 mutations in Breast Cancer
70
BCL2L1 20q11.21 BCLX, BCL2L, BCLXL, BCLXS, Bcl-X, bcl-xL, bcl-xS, PPP1R52, BCL-XL/S -BCL2L1 and Breast Cancer
70
RELA 11q13.1 p65, NFKB3 -RELA and Breast Cancer
69
HRAS 11p15.5 CTLO, HAMSV, HRAS1, RASH1, p21ras, C-H-RAS, H-RASIDX, C-BAS/HAS, C-HA-RAS1 -HRAS and Breast Cancer
69
SCGB2A2 11q12.3 MGB1, UGB2 -SCGB2A2 and Breast Cancer
69
TGFA 2p13 TFGA -TGFA and Breast Cancer
69
IGFBP3 7p12.3 IBP3, BP-53 -IGFBP3 and Breast Cancer
68
FLT1 13q12 FLT, FLT-1, VEGFR1, VEGFR-1 -FLT1 and Breast Cancer
68
CCNB1 5q12 CCNB -CCNB1 and Breast Cancer
68
PDLIM4 5q31.1 RIL -PDLIM4 and Breast Cancer
68
FGFR1 8p11.23-p11.22 CEK, FLG, HH2, OGD, FLT2, KAL2, BFGFR, CD331, FGFBR, FLT-2, HBGFR, N-SAM, FGFR-1, HRTFDS, bFGF-R-1 -FGFR1 and Breast Cancer
68
TWIST1 7p21.2 CRS, CSO, SCS, ACS3, CRS1, BPES2, BPES3, TWIST, bHLHa38 -TWIST1 and Breast Cancer
66
AKT2 19q13.1-q13.2 PKBB, PRKBB, HIHGHH, PKBBETA, RAC-BETA -AKT2 and Breast Cancer
65
FGF3 11q13.3 INT2, HBGF-3 -FGF3 and Breast Cancer
65
CYP3A5 7q21.1 CP35, PCN3, CYPIIIA5, P450PCN3 -CYP3A5 and Breast Cancer
64
BRAP 12q24 IMP, BRAP2, RNF52 -BRAP and Breast Cancer
63
FGF2 4q26 BFGF, FGFB, FGF-2, HBGF-2 -FGF2 and Breast Cancer
62
IL6 7p21 HGF, HSF, BSF2, IL-6, IFNB2 -IL6 and Breast Cancer
62
MYB 6q22-q23 efg, Cmyb, c-myb, c-myb_CDS -MYB and Breast Cancer
62
IGF2 11p15.5 GRDF, IGF-II, PP9974, C11orf43 -IGF2 and Breast Cancer
61
NAT2 8p22 AAC2, PNAT, NAT-2 -NAT2 and Breast Cancer
61
ACHE 7q22 YT, ACEE, ARACHE, N-ACHE -ACHE and Breast Cancer
60
H2AFX 11q23.3 H2AX, H2A.X, H2A/X -H2AFX and Breast Cancer
60
STK11 19p13.3 PJS, LKB1, hLKB1 -STK11 and Breast Cancer
60
AURKA 20q13 AIK, ARK1, AURA, BTAK, STK6, STK7, STK15, AURORA2, PPP1R47 -AURKA and Breast Cancer
60
TTPA 8q12.3 ATTP, AVED, TTP1, alphaTTP -TTPA and Breast Cancer
58
NBN 8q21 ATV, NBS, P95, NBS1, AT-V1, AT-V2 -NBN and Breast Cancer
58
IGF2R 6q26 MPR1, MPRI, CD222, CIMPR, M6P-R -IGF2R and Breast Cancer
57
RHOA 3p21.3 ARHA, ARH12, RHO12, RHOH12 -RHOA and Breast Cancer
57
RAC1 7p22 MIG5, Rac-1, TC-25, p21-Rac1 -RAC1 and Breast Cancer
56
EZH2 7q35-q36 WVS, ENX1, EZH1, KMT6, WVS2, ENX-1, EZH2b, KMT6A -EZH2 and Breast Cancer
55
MAP3K1 5q11.2 MEKK, MEKK1, SRXY6, MEKK 1, MAPKKK1 -MAP3K1 and Breast Cancer
55
NCOA3 20q12 ACTR, AIB1, RAC3, SRC3, pCIP, AIB-1, CTG26, SRC-3, CAGH16, KAT13B, TNRC14, TNRC16, TRAM-1, bHLHe42 -NCOA3 and Breast Cancer
55
ERCC2 19q13.3 EM9, TTD, XPD, TTD1, COFS2, TFIIH -ERCC2 and Breast Cancer
54
LSP1 11p15.5 WP34, pp52 -LSP1 and Breast Cancer
52
TFAP2B 6p12 AP-2B, AP2-B -TFAP2B and Breast Cancer
51
TFAP2A 6p24 AP-2, BOFS, AP2TF, TFAP2, AP-2alpha -TFAP2A Expression in Breast Cancer
51
ZEB1 10p11.2 BZP, TCF8, AREB6, FECD6, NIL2A, PPCD3, ZFHEP, ZFHX1A, DELTAEF1 -ZEB1 and Breast Cancer
50
FH 1q42.1 MCL, FMRD, LRCC, HLRCC, MCUL1 -FH and Breast Cancer
50
RAD51C 17q22 FANCO, R51H3, BROVCA3, RAD51L2 -RAD51C and Breast Cancer
50
TFAP2C 20q13.2 ERF1, TFAP2G, hAP-2g, AP2-GAMMA -TFAP2C and Breast Cancer
50
HSD17B2 16q24.1-q24.2 HSD17, SDR9C2, EDH17B2 -HSD17B2 and Breast Cancer
49
SMAD4 18q21.1 JIP, DPC4, MADH4, MYHRS -SMAD4 and Breast Cancer
48
WNT1 12q13 INT1, OI15, BMND16 -WNT1 and Breast Cancer
48
HDAC1 1p34 HD1, RPD3, GON-10, RPD3L1 -HDAC1 and Breast Cancer
47
RAD50 5q31 NBSLD, RAD502, hRad50 -RAD50 and Breast Cancer
47
HGF 7q21.1 SF, HGFB, HPTA, F-TCF, DFNB39 -HGF and Breast Cancer
47
ITGB1 10p11.2 CD29, FNRB, MDF2, VLAB, GPIIA, MSK12, VLA-BETA -ITGB1 (CD29) and Breast Cancer
47
GAPDH 12p13 G3PD, GAPD, HEL-S-162eP -GAPDH and Breast Cancer
46
DNMT1 19p13.2 AIM, DNMT, MCMT, CXXC9, HSN1E, ADCADN -DNMT1 and Breast Cancer
46
SHBG 17p13.1 ABP, SBP, TEBG -SHBG and Breast Cancer
46
MMP1 11q22.2 CLG, CLGN -MMP1 and Breast Cancer
45
TNFRSF11A 18q22.1 FEO, OFE, ODFR, OSTS, PDB2, RANK, CD265, OPTB7, TRANCER, LOH18CR1 -TNFRSF11A and Breast Cancer
45
EPCAM 2p21 ESA, KSA, M4S1, MK-1, DIAR5, EGP-2, EGP40, KS1/4, MIC18, TROP1, EGP314, HNPCC8, TACSTD1 -EPCAM and Breast Cancer
45
BRMS1 11q13.2 -BRMS1 and Breast Cancer
44
CDC42 1p36.1 G25K, CDC42Hs -CDC42 and Breast Cancer
44
NQO1 16q22.1 DTD, QR1, DHQU, DIA4, NMOR1, NMORI -NQO1 and Breast Cancer
44
ABCC1 16p13.1 MRP, ABCC, GS-X, MRP1, ABC29 -ABCC1 (MRP1) and Breast Cancer
42
GRB7 17q12 -GRB7 and Breast Cancer
42
IGF1 12q23.2 IGFI, IGF-I, IGF1A -IGF1 and Breast Cancer
42
TNFRSF10B 8p22-p21 DR5, CD262, KILLER, TRICK2, TRICKB, ZTNFR9, TRAILR2, TRICK2A, TRICK2B, TRAIL-R2, KILLER/DR5 -TNFRSF10B and Breast Cancer
41
TOX3 16q12.1 CAGF9, TNRC9 -TOX3 and Breast Cancer
41
KRT5 12q13.13 K5, CK5, DDD, DDD1, EBS2, KRT5A -KRT5 and Breast Cancer
41
SOD2 6q25.3 IPOB, MNSOD, MVCD6 -SOD2 and Breast Cancer
41
TGFBR2 3p22 AAT3, FAA3, LDS2, MFS2, RIIC, LDS1B, LDS2B, TAAD2, TGFR-2, TGFbeta-RII -TGFBR2 and Breast Cancer
40
ERBB4 2q33.3-q34 HER4, ALS19, p180erbB4 -ERBB4 and Breast Cancer
40
CAV1 7q31.1 CGL3, PPH3, BSCL3, LCCNS, VIP21, MSTP085 -CAV1 and Breast Cancer
39
NTRK3 15q25 TRKC, gp145(trkC) Translocation
-NTRK3 and Breast Cancer
-t(12;15)(p13;q25) ETV6-NTRK3 in Breast Cancer
33
STAT1 2q32.2 CANDF7, IMD31A, IMD31B, IMD31C, ISGF-3, STAT91 -STAT1 and Breast Cancer
39
CYP1A2 15q24.1 CP12, P3-450, P450(PA) -CYP1A2 and Breast Cancer
39
CCNE1 19q12 CCNE, pCCNE1 -CCNE1 and Breast Cancer
38
MMP3 11q22.2 SL-1, STMY, STR1, CHDS6, MMP-3, STMY1 -MMP3 and Breast Cancer
38
TNFSF11 13q14 ODF, OPGL, sOdf, CD254, OPTB2, RANKL, TRANCE, hRANKL2 -TNFSF11 and Breast Cancer
38
VEGFC 4q34.3 VRP, Flt4-L, LMPH1D -VEGFC and Breast Cancer
38
CYP2C19 10q24 CPCJ, CYP2C, P450C2C, CYPIIC17, CYPIIC19, P450IIC19 -CYP2C19 and Breast Cancer
37
BACH1 21q22.11 BACH-1, BTBD24 -BACH1 and Breast Cancer
36
CCND2 12p13 MPPH3, KIAK0002 -CCND2 and Breast Cancer
36
MCAM 11q23.3 CD146, MUC18 -MCAM and Breast Cancer
36
PTK2 8q24.3 FAK, FADK, FAK1, FRNK, PPP1R71, p125FAK, pp125FAK -PTK2 and Breast Cancer
35
PARL 3q27.1 PSARL, PSARL1, RHBDS1, PRO2207, PSENIP2 -PARL and Breast Cancer
35
OLAH 10p13 SAST, AURA1, THEDC1 -OLAH and Breast Cancer
34
ALDH1A1 9q21.13 ALDC, ALDH1, HEL-9, HEL12, PUMB1, ALDH11, RALDH1, ALDH-E1, HEL-S-53e -ALDH1A1 and Breast Cancer
34
CHIA 1p13.2 CHIT2, AMCASE, TSA1902 -CHIA and Breast Cancer
33
CHEK1 11q24.2 CHK1 -CHEK1 and Breast Cancer
33
PRLR 5p13.2 HPRL, MFAB, hPRLrI -PRLR and Breast Cancer
33
EIF4E 4q23 CBP, EIF4F, AUTS19, EIF4E1, EIF4EL1 -EIF4E and Breast Cancer
33
XRCC2 7q36.1 -XRCC2 and Breast Cancer
32
CXCL1 4q21 FSP, GRO1, GROa, MGSA, NAP-3, SCYB1, MGSA-a -CXCL1 and Breast Cancer
32
PDGFB 22q13.1 SIS, SSV, IBGC5, PDGF2, c-sis, PDGF-2 -PDGFB and Breast Cancer
32
SMAD2 18q21.1 JV18, MADH2, MADR2, JV18-1, hMAD-2, hSMAD2 -SMAD2 and Breast Cancer
32
GPER1 7p22.3 mER, CEPR, GPER, DRY12, FEG-1, GPR30, LERGU, LyGPR, CMKRL2, LERGU2, GPCR-Br -GPER and Breast Cancer
32
CD82 11p11.2 R2, 4F9, C33, IA4, ST6, GR15, KAI1, SAR2, TSPAN27 -CD82 and Breast Cancer
32
MTA1 14q32.3 -MTA1 and Breast Cancer
31
FAS 10q24.1 APT1, CD95, FAS1, APO-1, FASTM, ALPS1A, TNFRSF6 -FAS and Breast Cancer
31
IRS1 2q36 HIRS-1 -IRS1 and Breast Cancer
31
FOXO3 6q21 FOXO2, AF6q21, FKHRL1, FOXO3A, FKHRL1P2 -FOXO3 and Breast Cancer
31
BAG1 9p12 HAP, BAG-1, RAP46 Overexpression
-BAG1 overexpression in Breast Cancer
31
FOXM1 12p13 MPP2, TGT3, HFH11, HNF-3, INS-1, MPP-2, PIG29, FKHL16, FOXM1B, HFH-11, TRIDENT, MPHOSPH2 -FOXM1 and Breast Cancer
31
CTCF 16q21-q22.3 MRD21 -CTCF and Breast Cancer
31
S100A4 1q21 42A, 18A2, CAPL, FSP1, MTS1, P9KA, PEL98 -S100A4 and Breast Cancer
31
EGR1 5q31.1 TIS8, AT225, G0S30, NGFI-A, ZNF225, KROX-24, ZIF-268 -EGR1 and Breast Cancer
30
WWOX 16q23 FOR, WOX1, EIEE28, FRA16D, SCAR12, HHCMA56, PRO0128, SDR41C1, D16S432E -WWOX and Breast Cancer
30
ANXA8 10q11.22 ANX8, CH17-360D5.2 -ANXA8 and Breast Cancer
30
SFRP1 8p11.21 FRP, FRP1, FrzA, FRP-1, SARP2 -SFRP1 and Breast Cancer
30
AREG 4q13.3 AR, SDGF, AREGB, CRDGF -AREG and Breast Cancer
30
CTGF 6q23.1 CCN2, NOV2, HCS24, IGFBP8 -CTGF and Breast Cancer
29
FOXP3 Xp11.23 JM2, AIID, IPEX, PIDX, XPID, DIETER -FOXP3 and Breast Cancer
29
TIMP2 17q25 DDC8, CSC-21K Prognostic
-TIMP2 Expression in Breast Cancer
28
JUNB 19p13.2 AP-1 -JUNB and Breast Cancer
28
MDM4 1q32 HDMX, MDMX, MRP1 -MDM4 and Breast Cancer
28
PAK1 11q13.5-q14.1 PAKalpha -PAK1 and Breast Cancer
28
XPC 3p25.1 XP3, RAD4, XPCC, p125 -XPC and Breast Cancer
28
SOX2 3q26.3-q27 ANOP3, MCOPS3 -SOX2 and Breast Cancer
28
DROSHA 5p13.3 RN3, ETOHI2, RNASEN, RANSE3L, RNASE3L, HSA242976 -DROSHA and Breast Cancer
28
CDC25A 3p21 CDC25A2 -CDC25A and Breast Cancer
28
NCOA1 2p23 SRC1, KAT13A, RIP160, F-SRC-1, bHLHe42, bHLHe74 -NCOA1 and Breast Cancer
28
PPP2CB 8p12 PP2CB, PP2Abeta -PPP2CB and Breast Cancer
28
COIL 17q22 CLN80, p80-coilin -COIL and Breast Cancer
27
GRB2 17q24-q25 ASH, Grb3-3, MST084, NCKAP2, MSTP084, EGFRBP-GRB2 -GRB2 and Breast Cancer
27
PPP2CA 5q31.1 RP-C, PP2Ac, PP2CA, PP2Calpha -PPP2CA and Breast Cancer
27
ESR2 14q23.2 Erb, ESRB, ESTRB, NR3A2, ER-BETA, ESR-BETA -ESR2 and Breast Cancer
27
PLAUR 19q13 CD87, UPAR, URKR, U-PAR -PLAUR and Breast Cancer
27
JUND 19p13.2 AP-1 -JUND and Breast Cancer
27
MMP13 11q22.2 CLG3, MDST, MANDP1, MMP-13 -MMP13 and Breast Cancer
27
CCL2 17q11.2-q12 HC11, MCAF, MCP1, MCP-1, SCYA2, GDCF-2, SMC-CF, HSMCR30 -CCL2 and Breast Cancer
27
HEBP1 12p13.1 HBP, HEBP -HEBP1 and Breast Cancer
27
STAR 8p11.2 STARD1 -STAR and Breast Cancer
27
CBL 11q23.3 CBL2, NSLL, C-CBL, RNF55, FRA11B -Proto-Oncogene Proteins c-cbl and Breast Cancer
27
FGF4 11q13.3 HST, KFGF, HST-1, HSTF1, K-FGF, HBGF-4 -FGF4 and Breast Cancer
27
PIN1 19p13 DOD, UBL5 -PIN1 and Breast Cancer
26
CYP2C9 10q24 CPC9, CYP2C, CYP2C10, CYPIIC9, P450IIC9 -CYP2C9 and Breast Cancer
26
CYP2B6 19q13.2 CPB6, EFVM, IIB1, P450, CYP2B, CYP2B7, CYP2B7P, CYPIIB6 -CYP2B6 and Breast Cancer
26
TERC 3q26 TR, hTR, TRC3, DKCA1, PFBMFT2, SCARNA19 -TERC and Breast Cancer
26
DNMT3B 20q11.2 ICF, ICF1, M.HsaIIIB -DNMT3B and Breast Cancer
26
THBS1 15q15 TSP, THBS, TSP1, TSP-1, THBS-1 -THBS1 and Breast Cancer
26
TIMP3 22q12.3 SFD, K222, K222TA2, HSMRK222 -TIMP3 and Breast Cancer
26
RUNX2 6p21 CCD, AML3, CCD1, CLCD, OSF2, CBFA1, OSF-2, PEA2aA, PEBP2aA, CBF-alpha-1 -RUNX2 and Breast Cancer
26
TSG101 11p15.1 TSG10, VPS23 -TSG101 and Breast Cancer
26
MAF 16q22-q23 CCA4, AYGRP, c-MAF, CTRCT21 -MAF and Breast Cancer
26
LGALS3 14q22.3 L31, GAL3, MAC2, CBP35, GALBP, GALIG, LGALS2 -LGALS3 and Breast Cancer
26
TYMS 18p11.32 TS, TMS, HST422 -TYMS and Breast Cancer
26
STAT5A 17q11.2 MGF, STAT5 -STAT5A and Breast Cancer
26
TCF4 18q21.1 E2-2, ITF2, PTHS, SEF2, ITF-2, SEF-2, TCF-4, SEF2-1, SEF2-1A, SEF2-1B, SEF2-1D, bHLHb19 -TCF4 and Breast Cancer
26
MRE11 11q21 ATLD, HNGS1, MRE11A, MRE11B -MRE11A and Breast Cancer
25
ZNF217 20q13.2 ZABC1 -ZNF217 and Breast Cancer
25
PLK1 16p12.2 PLK, STPK13 -PLK1 and Breast Cancer
25
MTDH 8q22.1 3D3, AEG1, AEG-1, LYRIC, LYRIC/3D3 -MTDH and Breast Cancer
25
ZEB2 2q22.3 SIP1, SIP-1, ZFHX1B, HSPC082, SMADIP1 -ZEB2 and Breast Cancer
25
MMP11 22q11.23 ST3, SL-3, STMY3 Prognostic
-MMP11 Expression in Breast Cancer
25
FOXO1 13q14.1 FKH1, FKHR, FOXO1A -FOXO1 and Breast Cancer
25
SKP2 5p13 p45, FBL1, FLB1, FBXL1 -SKP2 and Breast Cancer
25
BECN1 17q21 ATG6, VPS30, beclin1 -BECN1 and Breast Cancer
25
CLOCK 4q12 KAT13D, bHLHe8 -CLOCK and Breast Cancer
25
SPARC 5q31.3-q32 ON -SPARC and Breast Cancer
24
SYK 9q22 p72-Syk -SYK and Breast Cancer
24
SIRT1 10q21.3 SIR2, hSIR2, SIR2L1 -SIRT1 and Breast Cancer
24
YAP1 11q22.1 YAP, YKI, COB1, YAP2, YAP65 -YAP1 and Breast Cancer
24
DIRAS3 1p31 ARHI, NOEY2 -DIRAS3 and Breast Cancer
24
BCAR1 16q23.1 CAS, CAS1, CASS1, CRKAS, P130Cas -BCAR1 and Breast Cancer
24
PECAM1 17q23.3 CD31, PECA1, GPIIA', PECAM-1, endoCAM, CD31/EndoCAM -PECAM1 and Breast Cancer
24
NRG1 8p12 GGF, HGL, HRG, NDF, ARIA, GGF2, HRG1, HRGA, SMDF, MST131, MSTP131, NRG1-IT2 -NRG1 and Breast Cancer
24
TP63 3q28 AIS, KET, LMS, NBP, RHS, p40, p51, p63, EEC3, OFC8, p73H, p73L, SHFM4, TP53L, TP73L, p53CP, TP53CP, B(p51A), B(p51B) -TP63 and Breast Cancer
23
PTK6 20q13.3 BRK -PTK6 and Breast Cancer
23
FGFR4 5q35.2 TKF, JTK2, CD334 -FGFR4 and Breast Cancer
23
CST6 11q13.1 -CST6 and Breast Cancer
23
SCGB3A1 5q35.3 HIN1, HIN-1, LU105, UGRP2, PnSP-2 -SCGB3A1 and Breast Cancer
23
CASP7 10q25 MCH3, CMH-1, LICE2, CASP-7, ICE-LAP3 -CASP7 and Breast Cancer
23
NANOG 12p13.31 -NANOG and Breast Cancer
23
HSD17B1 17q11-q21 HSD17, EDHB17, EDH17B2, SDR28C1 -HSD17B1 and Breast Cancer
23
SLC2A1 1p34.2 PED, DYT9, GLUT, DYT17, DYT18, EIG12, GLUT1, HTLVR, GLUT-1, GLUT1DS -GLUT1 expression in Breast Cancer
23
CCNA2 4q27 CCN1, CCNA -CCNA2 and Breast Cancer
22
TP53BP1 15q15-q21 p202, 53BP1 -TP53BP1 and Breast Cancer
22
ARHGEF1 19q13.13 LSC, GEF1, LBCL2, SUB1.5, P115-RHOGEF -ARHGEF1 and Breast Cancer
22
NAT1 8p22 AAC1, MNAT, NATI, NAT-1 -NAT1 and Breast Cancer
22
SNCG 10q23.2-q23.3 SR, BCSG1 -SNCG and Breast Cancer
22
NFE2L2 2q31 NRF2 -NFE2L2 and Breast Cancer
22
KISS1 1q32 HH13, KiSS-1 -KISS1 and Breast Cancer
22
RAD52 12p13-p12.2 -RAD52 and Breast Cancer
22
MIB1 18q11.2 MIB, DIP1, ZZZ6, DIP-1, LVNC7, ZZANK2 -MIB1 and Breast Cancer
22
CRK 17p13.3 p38, CRKII -CRK and Breast Cancer
22
E2F4 16q22.1 E2F-4 -E2F4 and Breast Cancer
22
PDCD4 10q24 H731 -PDCD4 and Breast Cancer
22
WNT5A 3p21-p14 hWNT5A -WNT5A and Breast Cancer
22
BUB1 2q14 BUB1A, BUB1L, hBUB1 -BUB1 and Breast Cancer
22
EPHA2 1p36 ECK, CTPA, ARCC2, CTPP1, CTRCT6 -EPHA2 and Breast Cancer
21
CDK1 10q21.1 CDC2, CDC28A, P34CDC2 -CDK1 and Breast Cancer
21
KLF4 9q31 EZF, GKLF -KLF4 and Breast Cancer
21
PELP1 17p13.2 MNAR, P160 -PELP1 and Breast Cancer
21
PTHLH 12p12.1-p11.2 HHM, PLP, BDE2, PTHR, PTHRP -PTHLH and Breast Cancer
21
TRPM2 21q22.3 KNP3, EREG1, TRPC7, LTRPC2, NUDT9H, NUDT9L1 -TRPM2 and Breast Cancer
21
TFF3 21q22.3 ITF, P1B, TFI -TFF3 and Breast Cancer
21
LEPR 1p31 OBR, OB-R, CD295, LEP-R, LEPRD -LEPR and Breast Cancer
21
MIR126 9q34.3 MIRN126, mir-126, miRNA126 -MicroRNA mir-126 and Breast Cancer
21
NOTCH2 1p13-p11 hN2, AGS2, HJCYS -NOTCH2 and Breast Cancer
21
CCL5 17q12 SISd, eoCP, SCYA5, RANTES, TCP228, D17S136E, SIS-delta -CCL5 and Breast Cancer
21
HMOX1 22q13.1 HO-1, HSP32, HMOX1D, bK286B10 -HMOX1 and Breast Cancer
21
RAP1A 1p13.3 RAP1, C21KG, G-22K, KREV1, KREV-1, SMGP21 -Breast Cancer and RAP1A
21
NOS3 7q36 eNOS, ECNOS -NOS3 and Breast Cancer
20
CYP24A1 20q13 CP24, HCAI, CYP24, P450-CC24 -CYP24A1 and Breast Cancer
20
LOX 5q23.2 -LOX and Breast Cancer
20
NCOR1 17p11.2 N-CoR, TRAC1, N-CoR1, hN-CoR, PPP1R109 -NCOR1 and Breast Cancer
20
FTCDNL1 2q33.1 FONG -FONG and Breast Cancer
20
OSCAR 19q13.42 PIGR3, PIgR-3 -OSCAR and Breast Cancer
20
ELAVL1 19p13.2 HUR, Hua, MelG, ELAV1 -ELAVL1 and Breast Cancer
20
POLE 12q24.3 FILS, POLE1, CRCS12 -POLE and Breast Cancer
20
FBXW7 4q31.3 AGO, CDC4, FBW6, FBW7, hAgo, FBX30, FBXW6, SEL10, hCdc4, FBXO30, SEL-10 -FBXW7 and Breast Cancer
20
EP300 22q13.2 p300, KAT3B, RSTS2 -EP300 and Breast Cancer
20
FGF1 5q31 AFGF, ECGF, FGFA, ECGFA, ECGFB, FGF-1, HBGF1, HBGF-1, GLIO703, ECGF-beta, FGF-alpha -FGF1 and Breast Cancer
19
CD9 12p13.3 MIC3, MRP-1, BTCC-1, DRAP-27, TSPAN29, TSPAN-29 -CD9 expression in Breast Cancer
19
TNFRSF11B 8q24 OPG, TR1, OCIF -TNFRSF11B and Breast Cancer
19
M6PR 12p13 SMPR, MPR46, CD-MPR, MPR 46, MPR-46 -M6PR and Breast Cancer
19
PPM1D 17q23.2 WIP1, PP2C-DELTA -PPM1D and Breast Cancer
19
SPP1 4q22.1 OPN, BNSP, BSPI, ETA-1 -SPP1 and Breast Cancer
19
CREB1 2q34 CREB -CREB1 and Breast Cancer
19
CLU 8p21-p12 CLI, AAG4, APOJ, CLU1, CLU2, KUB1, SGP2, APO-J, SGP-2, SP-40, TRPM2, TRPM-2, NA1/NA2 -CLU and Breast Cancer
19
GSTA1 6p12.1 GST2, GTH1, GSTA1-1 -GSTA1 and Breast Cancer
19
EIF4EBP1 8p12 BP-1, 4EBP1, 4E-BP1, PHAS-I -EIF4EBP1 and Breast Cancer
19
CDH13 16q23.3 CDHH, P105 -CDH13 and Breast Cancer
19
POU5F1 6p21.31 OCT3, OCT4, OTF3, OTF4, OTF-3, Oct-3, Oct-4 -POU5F1 and Breast Cancer
19
DDIT3 12q13.1-q13.2 CHOP, CEBPZ, CHOP10, CHOP-10, GADD153 -DDIT3 and Breast Cancer
19
POLL 10q23 BETAN, POLKAPPA -POLL and Breast Cancer
19
APOE 19q13.2 AD2, LPG, APO-E, LDLCQ5 -APOE and Breast Cancer
18
HIC1 17p13.3 hic-1, ZBTB29, ZNF901 -HIC1 and Breast Cancer
18
ERCC4 16p13.12 XPF, RAD1, FANCQ, ERCC11 -ERCC4 and Breast Cancer
18
AKT3 1q44 MPPH, PKBG, MPPH2, PRKBG, STK-2, PKB-GAMMA, RAC-gamma, RAC-PK-gamma -AKT3 and Breast Cancer
18
CTTN 11q13.3 EMS1 -CTTN and Breast Cancer
18
S100A7 1q21 PSOR1, S100A7c -S100A7 and Breast Cancer
18
IGFBP1 7p12.3 AFBP, IBP1, PP12, IGF-BP25, hIGFBP-1 -IGFBP1 and Breast Cancer
18
CSK 15q24.1 -CSK and Breast Cancer
18
ITGB4 17q25 CD104 -ITGB4 and Breast Cancer
18
MYBL2 20q13.1 BMYB, B-MYB -MYBL2 and Breast Cancer
18
NOTCH3 19p13.12 IMF2, LMNS, CASIL, CADASIL, CADASIL1 -NOTCH3 and Breast Cancer
18
ID2 2p25 GIG8, ID2A, ID2H, bHLHb26 -ID2 Expression in Breast Cancer
18
SCFV 14 -SCFV and Breast Cancer
18
MMP14 14q11.2 MMP-14, MMP-X1, MT-MMP, MT1MMP, MTMMP1, WNCHRS, MT1-MMP, MT-MMP 1 -MMP14 and Breast Cancer
18
OGG1 3p26.2 HMMH, MUTM, OGH1, HOGG1 -OGG1 and Breast Cancer
18
CDC25C 5q31 CDC25, PPP1R60 -CDC25C and Breast Cancer
17
STAT5B 17q11.2 STAT5 -STAT5B and Breast Cancer
17
MECP2 Xq28 RS, RTS, RTT, PPMX, MRX16, MRX79, MRXSL, AUTSX3, MRXS13 -MECP2 and Breast Cancer
17
HFE 6p21.3 HH, HFE1, HLA-H, MVCD7, TFQTL2 -HFE and Breast Cancer
17
CTLA4 2q33 CD, GSE, GRD4, ALPS5, CD152, CTLA-4, IDDM12, CELIAC3 -CTLA4 and Breast Cancer
17
CCND3 6p21 -CCND3 and Breast Cancer
17
DNMT3A 2p23 TBRS, DNMT3A2, M.HsaIIIA -DNMT3A and Breast Cancer
17
XRCC4 5q14.2 -XRCC4 and Breast Cancer
17
ETS2 21q22.2 ETS2IT1 -ETS2 and Breast Cancer
17
TCF7L2 10q25.3 TCF4, TCF-4 -TCF7L2 and Breast Cancer
17
ELK1 Xp11.2 -ELK1 and Breast Cancer
17
MTRR 5p15.31 MSR, cblE -MTRR and Breast Cancer
17
YBX1 1p34 YB1, BP-8, CSDB, DBPB, YB-1, CSDA2, NSEP1, NSEP-1, MDR-NF1 -YBX1 and Breast Cancer
17
AGR2 7p21.3 AG2, GOB-4, HAG-2, XAG-2, PDIA17, HEL-S-116 -AGR2 and Breast Cancer
17
PITX2 4q25 RS, RGS, ARP1, Brx1, IDG2, IGDS, IHG2, PTX2, RIEG, IGDS2, IRID2, Otlx2, RIEG1 -PITX2 and Breast Cancer
16
SATB1 3p23 -SATB1 and Breast Cancer
16
SPDEF 6p21.3 PDEF, bA375E1.3 -SPDEF and Breast Cancer
16
FES 15q26.1 FPS -FES and Breast Cancer
16
ACTB 7p22 BRWS1, PS1TP5BP1 -ACTB and Breast Cancer
16
CYR61 1p22.3 CCN1, GIG1, IGFBP10 -CYR61 and Breast Cancer
16
PRKCA 17q22-q23.2 AAG6, PKCA, PRKACA, PKC-alpha -PRKCA and Breast Cancer
16
TLR4 9q33.1 TOLL, CD284, TLR-4, ARMD10 -TLR4 and Breast Cancer
16
NOTCH4 6p21.3 INT3 -NOTCH4 and Breast Cancer
16
CREBBP 16p13.3 CBP, RSTS, KAT3A -CREBBP and Breast Cancer
16
FEN1 11q12.2 MF1, RAD2, FEN-1 -FEN1 and Breast Cancer
16
GREB1 2p25.1 -GREB1 and Breast Cancer
16
VIP 6q25 PHM27 -VIP and Breast Cancer
16
HDAC3 5q31 HD3, RPD3, RPD3-2 -HDAC3 and Breast Cancer
16
GPX1 3p21.3 GPXD, GSHPX1 -GPX1 and Breast Cancer
16
CYP2C8 10q23.33 CPC8, CYPIIC8, MP-12/MP-20 -CYP2C8 and Breast Cancer
16
JAG1 20p12.1-p11.23 AGS, AHD, AWS, HJ1, CD339, JAGL1 -JAG1 and Breast Cancer
15
RARB 3p24.2 HAP, RRB2, NR1B2, MCOPS12 -RARB and Breast Cancer
15
CLDN1 3q28-q29 CLD1, SEMP1, ILVASC -CLDN1 and Breast Cancer
15
NEK2 1q32.3 NLK1, RP67, NEK2A, HsPK21, PPP1R111 -NEK2 and Breast Cancer
15
SIPA1 11q13.1 SPA1 -SIPA1 and Breast Cancer
15
PIK3CB 3q22.3 PI3K, PIK3C1, P110BETA, PI3KBETA -PIK3CB and Breast Cancer
15
DLC1 8p22 HP, ARHGAP7, STARD12, p122-RhoGAP -Breast Cancer and DLC1
15
APOD 3q29 -APOD and Breast Cancer
15
RRM2 2p25-p24 R2, RR2, RR2M -RRM2 and Breast Cancer
15
WISP2 20q13.12 CCN5, CT58, CTGF-L -WISP2 and Breast Cancer
15
ITGB3 17q21.32 GT, CD61, GP3A, BDPLT2, GPIIIa, BDPLT16 -ITGB3 and Breast Cancer
15
FOXC1 6p25 ARA, IGDA, IHG1, FKHL7, IRID1, RIEG3, FREAC3, FREAC-3 -FOXC1 and Breast Cancer
15
PTTG1 5q35.1 EAP1, PTTG, HPTTG, TUTR1 -PTTG1 and Breast Cancer
15
NOS2 17q11.2 NOS, INOS, NOS2A, HEP-NOS -NOS2 and Breast Cancer
15
MARCO 2q14.2 SCARA2 -MARCO and Breast Cancer
15
MBD2 18q21 DMTase, NY-CO-41 -MBD2 and Breast Cancer
15
CXCL2 4q21 GRO2, GROb, MIP2, MIP2A, SCYB2, MGSA-b, MIP-2a, CINC-2a -CXCL2 and Breast Cancer
15
RELB 19q13.32 IREL, I-REL, REL-B -RELB and Breast Cancer
15
WEE1 11p15.4 WEE1A, WEE1hu -WEE1 and Breast Cancer
15
BBC3 19q13.3-q13.4 JFY1, PUMA, JFY-1 -BBC3 and Breast Cancer
15
CTNNA1 5q31.2 CAP102 -CTNNA1 and Breast Cancer
15
TIAM1 21q22.11 -TIAM1 and Breast Cancer
15
RRM1 11p15.4 R1, RR1, RIR1 -RRM1 and Breast Cancer
15
FYN 6q21 SLK, SYN, p59-FYN -FYN and Breast Cancer
14
BAP1 3p21.1 UCHL2, hucep-6, HUCEP-13 -BAP1 and Breast Cancer
14
UBE2C 20q13.12 UBCH10, dJ447F3.2 -UBE2C and Breast Cancer
14
NFKB1 4q24 p50, KBF1, p105, EBP-1, NF-kB1, NFKB-p50, NFkappaB, NF-kappaB, NFKB-p105, NF-kappa-B -NFKB1 and Breast Cancer
14
WNT3 17q21 INT4, TETAMS -WNT3 and Breast Cancer
14
IL11 19q13.3-q13.4 AGIF, IL-11 -IL11 and Breast Cancer
14
PDK1 2q31.1 -PDK1 and Breast Cancer
14
REL 2p13-p12 C-Rel -REL and Breast Cancer
14
TNFRSF10A 8p21 DR4, APO2, CD261, TRAILR1, TRAILR-1 -TNFRSF10A and Breast Cancer
14
IRS2 13q34 IRS-2 -IRS2 and Breast Cancer
14
SNAI1 20q13.2 SNA, SNAH, SNAIL, SLUGH2, SNAIL1, dJ710H13.1 -SNAI1 and Breast Cancer
14
TGFB2 1q41 LDS4, TGF-beta2 -TGFB2 and Breast Cancer
14
CYP27B1 12q14.1 VDR, CP2B, CYP1, PDDR, VDD1, VDDR, VDDRI, CYP27B, P450c1, CYP1alpha -CYP27B1 and Breast Cancer
14
CD68 17p13 GP110, LAMP4, SCARD1 -CD68 and Breast Cancer
14
MALAT1 11q13.1 HCN, NEAT2, PRO2853, LINC00047, NCRNA00047 -MALAT1 and Breast Cancer
14
RAD51B 14q23-q24.2 REC2, R51H2, RAD51L1 -RAD51B and Breast Cancer
14
SRD5A2 2p23 -SRD5A2 and Breast Cancer
14
ARNT 1q21 HIF1B, TANGO, bHLHe2, HIF1BETA, HIF-1beta, HIF1-beta, HIF-1-beta -ARNT and Breast Cancer
14
E2F3 6p22 E2F-3 -E2F3 and Breast Cancer
14
KLK10 19q13 NES1, PRSSL1 -KLK10 and Breast Cancer
14
BNIP3 10q26.3 NIP3 -BNIP3 and Breast Cancer
14
DLX4 17q21.33 BP1, DLX7, DLX8, DLX9 -DLX4 and Breast Cancer
14
IGFBP5 2q35 IBP5 -IGFBP5 and Breast Cancer
14
SSTR2 17q24 -SSTR2 and Breast Cancer
14
RAD51D 17q11 TRAD, R51H3, BROVCA4, RAD51L3 -RAD51D and Breast Cancer
14
NCOR2 12q24 SMRT, TRAC, CTG26, SMRTE, TRAC1, N-CoR2, TNRC14, TRAC-1, SMAP270, SMRTE-tau -NCOR2 and Breast Cancer
14
ZNF350 19q13.41 ZFQR, ZBRK1 -ZNF350 and Breast Cancer
14
HSPB1 7q11.23 CMT2F, HMN2B, HSP27, HSP28, Hsp25, SRP27, HS.76067, HEL-S-102 -HSPB1 and Breast Cancer
14
PEBP1 12q24.23 PBP, HCNP, PEBP, RKIP, HCNPpp, PEBP-1, HEL-210, HEL-S-34 -PEBP1 and Breast Cancer
14
MIRLET7B 22q13.31 LET7B, let-7b, MIRNLET7B, hsa-let-7b -MicroRNA let-7b and Breast Cancer
14
E2F2 1p36 E2F-2 -E2F2 and Breast Cancer
13
BMP6 6p24-p23 VGR, VGR1 -BMP6 and Breast Cancer
13
HDAC6 Xp11.23 HD6, JM21, CPBHM, PPP1R90 -HDAC6 and Breast Cancer
13
MED1 17q12 PBP, CRSP1, RB18A, TRIP2, PPARBP, CRSP200, DRIP205, DRIP230, PPARGBP, TRAP220 -MED1 and Breast Cancer
13
PARK2 6q25.2-q27 PDJ, PRKN, AR-JP, LPRS2 -PARK2 and Breast Cancer
13
HOXD10 2q31.1 HOX4, HOX4D, HOX4E, Hox-4.4 -HOXD10 and Breast Cancer
13
RHOB 2p24 ARH6, ARHB, RHOH6, MST081, MSTP081 -RHOB and Breast Cancer
13
BRD4 19p13.1 CAP, MCAP, HUNK1, HUNKI -BRD4 and Breast Cancer
13
MOS 8q11 MSV -MOS and Breast Cancer
13
HDAC2 6q21 HD2, RPD3, YAF1 -HDAC2 and Breast Cancer
13
RAD21 8q24 HR21, MCD1, NXP1, SCC1, CDLS4, hHR21, HRAD21 -RAD21 and Breast Cancer
13
SHC1 1q21 SHC, SHCA -SHC1 and Breast Cancer
13
MAD2L1 4q27 MAD2, HSMAD2 -MAD2L1 and Breast Cancer
13
FASN 17q25 FAS, OA-519, SDR27X1 -FASN and Breast Cancer
13
IGFBP4 17q21.2 BP-4, IBP4, IGFBP-4, HT29-IGFBP -IGFBP4 and Breast Cancer
13
PRKDC 8q11 HYRC, p350, DNAPK, DNPK1, HYRC1, IMD26, XRCC7, DNA-PKcs -PRKDC and Breast Cancer
13
VIM 10p13 HEL113, CTRCT30 -VIM and Breast Cancer
13
SNAI2 8q11 SLUG, WS2D, SLUGH1, SNAIL2 -SNAI2 and Breast Cancer
13
HLA-G 6p21.3 MHC-G -HLA-G and Breast Cancer
13
CIC 19q13.2 -CIC and Breast Cancer
13
KDR 4q11-q12 FLK1, CD309, VEGFR, VEGFR2 -KDR and Breast Cancer
13
GADD45A 1p31.2 DDIT1, GADD45 -GADD45A and Breast Cancer
13
SIX1 14q23.1 BOS3, TIP39, DFNA23 -SIX1 and Breast Cancer
13
CCNE2 8q22.1 CYCE2 -CCNE2 and Breast Cancer
12
CAST 5q15 BS-17, PLACK -CAST and Breast Cancer
12
TACSTD2 1p32 EGP1, GP50, M1S1, EGP-1, TROP2, GA7331, GA733-1 -TACSTD2 and Breast Cancer
12
KRT19 17q21.2 K19, CK19, K1CS -KRT19 and Breast Cancer
12
TRPS1 8q24.12 GC79, LGCR -TRPS1 and Breast Cancer
12
TPM3 1q21.2 TM3, TM5, TRK, CFTD, NEM1, TM-5, TM30, CAPM1, TM30nm, TPMsk3, hscp30, HEL-189, HEL-S-82p, OK/SW-cl.5 -TPM3 and Breast Cancer
12
MAP2K4 17p12 JNKK, MEK4, MKK4, SEK1, SKK1, JNKK1, SERK1, MAPKK4, PRKMK4, SAPKK1, SAPKK-1 -MAP2K4 and Breast Cancer
12
MSN Xq11.1 HEL70 -MSN and Breast Cancer
12
STMN1 1p36.11 Lag, SMN, OP18, PP17, PP19, PR22, LAP18, C1orf215 -STMN1 and Breast Cancer
12
CARM1 19p13.2 PRMT4 -CARM1 and Breast Cancer
12
PWAR1 15q11.2 PAR1, PAR-1, D15S227E -PAR1 and Breast Cancer
12
WISP3 6q21 PPD, CCN6, LIBC, PPAC, WISP-3 -WISP3 and Breast Cancer
12
TOPBP1 3q22.1 TOP2BP1 -TOPBP1 and Breast Cancer
12
ADAM12 10q26 MCMP, MLTN, CAR10, MLTNA, MCMPMltna, ADAM12-OT1 -ADAM12 and Breast Cancer
12
RFC1 4p14-p13 A1, RFC, PO-GA, RECC1, MHCBFB, RFC140 -RFC1 and Breast Cancer
12
CCR7 17q12-q21.2 BLR2, EBI1, CCR-7, CD197, CDw197, CMKBR7, CC-CKR-7 -CCR7 and Breast Cancer
12
IL18 11q23.1 IGIF, IL-18, IL-1g, IL1F4 -IL18 and Breast Cancer
12
ANXA5 4q27 PP4, ANX5, ENX2, RPRGL3, HEL-S-7 -ANXA5 and Breast Cancer
12
HOXB7 17q21.3 HOX2, HOX2C, HHO.C1, Hox-2.3 -HOXB7 and Breast Cancer
12
AMPH 7p14-p13 AMPH1 Overexpression
-AMPH Expression in Stiff-Person Syndrome associated Breast Cancer
12
HAS2 8q24.12 -HAS2 and Breast Cancer
12
LMO4 1p22.3 -LMO4 and Breast Cancer
12
CCR5 3p21.31 CKR5, CCR-5, CD195, CKR-5, CCCKR5, CMKBR5, IDDM22, CC-CKR-5 -CCR5 and Breast Cancer
12
CDC20 1p34.1 CDC20A, p55CDC, bA276H19.3 -CDC20 and Breast Cancer
11
LCN2 9q34 24p3, MSFI, NGAL -LCN2 and Breast Cancer
11
EIF3E 8q22-q23 INT6, EIF3S6, EIF3-P48, eIF3-p46 -EIF3E and Breast Cancer
11
HOXA5 7p15.2 HOX1, HOX1C, HOX1.3 -HOXA5 and Breast Cancer
11
MARS 12q13.3 MRS, ILLD, CMT2U, ILFS2, METRS, MTRNS, SPG70 -MARS and Breast Cancer
11
SERPINB5 18q21.33 PI5, maspin -SERPINB5 and Breast Cancer
11
BMP4 14q22-q23 ZYME, BMP2B, OFC11, BMP2B1, MCOPS6 -BMP4 and Breast Cancer
11
HSF1 8q24.3 HSTF1 -HSF1 and Breast Cancer
11
ALCAM 3q13.1 MEMD, CD166 -ALCAM and Breast Cancer
11
RBBP8 18q11.2 RIM, COM1, CTIP, JWDS, SAE2, SCKL2 -RBBP8 and Breast Cancer
11
NFIB 9p24.1 CTF, NF1-B, NFI-B, NFIB2, NFIB3, NF-I/B, NFI-RED, HMGIC/NFIB -NFIB and Breast Cancer
11
TBX2 17q23.2 -TBX2 and Breast Cancer
11
CKAP4 12q23.3 p63, CLIMP-63, ERGIC-63 -CKAP4 and Breast Cancer
11
GDF15 19p13.11 PDF, MIC1, PLAB, MIC-1, NAG-1, PTGFB, GDF-15 -GDF15 and Breast Cancer
11
AKR1C3 10p15-p14 DD3, DDX, PGFS, HAKRB, HAKRe, HA1753, HSD17B5, hluPGFS -AKR1C3 and Breast Cancer
11
RPS6KB1 17q23.1 S6K, PS6K, S6K1, STK14A, p70-S6K, p70 S6KA, p70-alpha, S6K-beta-1, p70(S6K)-alpha -RPS6KB1 and Breast Cancer
11
BTG2 1q32 PC3, TIS21 -BTG2 and Breast Cancer
11
PYCARD 16p11.2 ASC, TMS, TMS1, CARD5, TMS-1 -PYCARD and Breast Cancer
11
CRP 1q23.2 PTX1 -CRP and Breast Cancer
11
PIGS 17p13.2 -PIGS and Breast Cancer
11
MAPK8 10q11.22 JNK, JNK1, PRKM8, SAPK1, JNK-46, JNK1A2, SAPK1c, JNK21B1/2 -MAPK8 and Breast Cancer
11
DHFR 5q14.1 DYR, DHFRP1 -DHFR and Breast Cancer
10
BIRC3 11q22.2 AIP1, API2, MIHC, CIAP2, HAIP1, HIAP1, MALT2, RNF49, c-IAP2 -BIRC3 and Breast Cancer
10
TUBB3 16q24.3 CDCBM, FEOM3, TUBB4, CDCBM1, CFEOM3, beta-4, CFEOM3A -TUBB3 and Breast Cancer
10
TRAF2 9q34 TRAP, TRAP3, MGC:45012 -TRAF2 and Breast Cancer
10
HMGB1 13q12 HMG1, HMG3, SBP-1 -HMGB1 and Breast Cancer
10
MTA2 11q12.3 PID, MTA1L1 -MTA2 and Breast Cancer
10
KLF5 13q22.1 CKLF, IKLF, BTEB2 -KLF5 and Breast Cancer
10
IBSP 4q21.1 BSP, BNSP, SP-II, BSP-II -IBSP and Breast Cancer
10
CDC25B 20p13 -CDC25B and Breast Cancer
10
ATF4 22q13.1 CREB2, TXREB, CREB-2, TAXREB67 -ATF4 and Breast Cancer
10
ADIPOR1 1q32.1 CGI45, PAQR1, ACDCR1, CGI-45, TESBP1A -ADIPOR1 and Breast Cancer
10
ELF3 1q32.2 ERT, ESX, EPR-1, ESE-1 -ELF3 and Breast Cancer
10
NDRG1 8q24.3 GC4, RTP, DRG1, NDR1, NMSL, TDD5, CAP43, CMT4D, DRG-1, HMSNL, RIT42, TARG1, PROXY1 -NDRG1 and Breast Cancer
10
SOD1 21q22.11 ALS, SOD, ALS1, IPOA, hSod1, HEL-S-44, homodimer -SOD1 and Breast Cancer
10
HOTAIR 12q13.13 HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072 -HOTAIR and Breast Cancer
10
FURIN 15q26.1 FUR, PACE, SPC1, PCSK3 -FURIN and Breast Cancer
10
BLM 15q26.1 BS, RECQ2, RECQL2, RECQL3 -BLM and Breast Cancer
10
BIK 22q13.31 BP4, NBK, BIP1 -BIK and Breast Cancer
10
FOXC2 16q24.1 LD, MFH1, MFH-1, FKHL14 -FOXC2 and Breast Cancer
10
CEBPD 8p11.2-p11.1 CELF, CRP3, C/EBP-delta, NF-IL6-beta -CEBPD and Breast Cancer
10
CLDN4 7q11.23 CPER, CPE-R, CPETR, CPETR1, WBSCR8, hCPE-R -CLDN4 and Breast Cancer
10
S100A8 1q21 P8, MIF, NIF, CAGA, CFAG, CGLA, L1Ag, MRP8, CP-10, MA387, 60B8AG -S100A8 and Breast Cancer
10
ST3 11q13-q23 CCTS, TSHL -ST3 and Breast Cancer
10
CUL4A 13q34 -CUL4A and Breast Cancer
10
RAF1 3p25 NS5, CRAF, Raf-1, c-Raf, CMD1NN -RAF1 and Breast Cancer
10
BCAR3 1p22.1 NSP2, SH2D3B -BCAR3 and Breast Cancer
10
CTSD 11p15.5 CPSD, CLN10, HEL-S-130P -CTSD and Breast Cancer
10
IRF1 5q31.1 MAR, IRF-1 -IRF1 and Breast Cancer
10
SDC1 2p24.1 SDC, CD138, SYND1, syndecan -SDC1 and Breast Cancer
10
DDB2 11p11.2 XPE, DDBB, UV-DDB2 -DDB2 and Breast Cancer
10
TBX3 12q24.21 UMS, XHL, TBX3-ISO -TBX3 and Breast Cancer
10
TLR3 4q35 CD283, IIAE2 -TLR3 and Breast Cancer
10
GHRH 20q11.2 GRF, INN, GHRF -GHRH and Breast Cancer
10
WNT3A 1q42 -WNT3A and Breast Cancer
10
UGT2B7 4q13 UGT2B9, UDPGTH2, UDPGT2B7, UDPGT 2B9 -UGT2B7 and Breast Cancer
10
ANXA1 9q21.13 ANX1, LPC1 -ANXA1 and Breast Cancer
10
ATG5 6q21 ASP, APG5, APG5L, hAPG5, APG5-LIKE -ATG5 and Breast Cancer
10
TGFB3 14q24 ARVD, RNHF, ARVD1, TGF-beta3 -TGFB3 and Breast Cancer
10
KL 13q12 -KL and Breast Cancer
10
ADH1C 4q23 ADH3 -ADH1C and Breast Cancer
10
NME2 17q21.3 PUF, NDKB, NDPKB, NM23B, NDPK-B, NM23-H2 -NME2 and Breast Cancer
10
COPS5 8q13.1 CSN5, JAB1, SGN5, MOV-34 -COPS5 and Breast Cancer
9
PTPN13 4q21.3 PNP1, FAP-1, PTP1E, PTPL1, PTPLE, PTP-BL, hPTP1E, PTP-BAS -PTPN13 and Breast Cancer
9
LIG4 13q33-q34 LIG4S -LIG4 and Breast Cancer
9
SOCS3 17q25.3 CIS3, SSI3, ATOD4, Cish3, SSI-3, SOCS-3 -SOCS3 and Breast Cancer
9
MALL 2q13 BENE -MALL and Breast Cancer
9
RARS 5q35.1 HLD9, ArgRS, DALRD1 -RARS and Breast Cancer
9
WARS 14q32.31 IFI53, IFP53, GAMMA-2 -WARS and Breast Cancer
9
PLAU 10q22.2 ATF, QPD, UPA, URK, u-PA, BDPLT5 -PLAU and Breast Cancer
9
RECK 9p13.3 ST15 -RECK and Breast Cancer
9
TCF3 19p13.3 E2A, E47, ITF1, VDIR, TCF-3, bHLHb21 -TCF3 and Breast Cancer
9
RHOBTB2 8p21.3 DBC2 -RHOBTB2 and Breast Cancer
9
SIRT3 11p15.5 SIR2L3 -SIRT3 and Breast Cancer
9
IL1B 2q14 IL-1, IL1F2, IL1-BETA -IL1B and Breast Cancer
9
TGFBR3 1p33-p32 BGCAN, betaglycan -TGFBR3 and Breast Cancer
9
TES 7q31.2 TESS, TESS-2 -TES and Breast Cancer
9
NFKB2 10q24 p52, p100, H2TF1, LYT10, CVID10, LYT-10, NF-kB2 -NFKB2 and Breast Cancer
9
IGFBP2 2q35 IBP2, IGF-BP53 -IGFBP2 and Breast Cancer
9
WIF1 12q14.3 WIF-1 -WIF1 and Breast Cancer
9
YWHAZ 8q23.1 HEL4, YWHAD, KCIP-1, HEL-S-3, 14-3-3-zeta -YWHAZ and Breast Cancer
9
SOX4 6p22.3 EVI16 -SOX4 and Breast Cancer
9
PSEN2 1q42.13 AD4, PS2, AD3L, STM2, CMD1V -PSEN2 and Breast Cancer
9
SFRP2 4q31.3 FRP-2, SARP1, SDF-5 -SFRP2 and Breast Cancer
9
ARID1A 1p35.3 ELD, B120, OSA1, P270, hELD, BM029, MRD14, hOSA1, BAF250, C1orf4, BAF250a, SMARCF1 -ARID1A and Breast Cancer
9
FGF8 10q24 HH6, AIGF, KAL6, FGF-8, HBGF-8 -FGF8 and Breast Cancer
9
BMP2 20p12 BDA2, BMP2A -BMP2 and Breast Cancer
9
CXCL10 4q21 C7, IFI10, INP10, IP-10, crg-2, mob-1, SCYB10, gIP-10 -CXCL10 and Breast Cancer
9
ATF3 1q32.3 -ATF3 and Breast Cancer
9
PIK3R1 5q13.1 p85, AGM7, GRB1, IMD36, p85-ALPHA -PIK3R1 and Breast Cancer
9
FCGR3A 1q23 CD16, FCG3, CD16A, FCGR3, IGFR3, IMD20, FCR-10, FCRIII, FCGRIII, FCRIIIA -FCGR3A and Breast Cancer
9
TRA 14q11.2 IMD7, TCRA, TCRD, TRA@, TRAC -TRA and Breast Cancer
9
TLR9 3p21.3 CD289 -TLR9 and Breast Cancer
9
COL1A1 17q21.33 OI1, OI2, OI3, OI4, EDSC -COL1A1 and Breast Cancer
9
CSF1 1p13.3 MCSF, CSF-1 -CSF1 and Breast Cancer
9
MUTYH 1p34.1 MYH -MUTYH and Breast Cancer
9
PER2 2q37.3 FASPS, FASPS1 -PER2 and Breast Cancer
9
DKK3 11p15.3 RIG, REIC -DKK3 and Breast Cancer
9
MDC1 6p21.3 NFBD1 -MDC1 and Breast Cancer
9
LIF 22q12.2 CDF, DIA, HILDA, MLPLI -LIF and Breast Cancer
9
IL17A 6p12 IL17, CTLA8, IL-17, IL-17A -IL17A and Breast Cancer
9
CCNB2 15q22.2 HsT17299 -CCNB2 and Breast Cancer
9
YES1 18p11.31-p11.21 Yes, c-yes, HsT441, P61-YES -Proto-Oncogene Proteins c-yes and Breast Cancer
9
ANGPT2 8p23.1 ANG2, AGPT2 -ANGPT2 and Breast Cancer
9
TPD52 8q21.13 D52, N8L, PC-1, PrLZ, hD52 -TPD52 and Breast Cancer
9
ABCC2 10q24 DJS, MRP2, cMRP, ABC30, CMOAT -ABCC2 and Breast Cancer
9
AGO2 8q24 Q10, EIF2C2 -EIF2C2 and Breast Cancer
9
RAB25 1q22 CATX-8, RAB11C -RAB25 and Breast Cancer
9
TP73 1p36.3 P73 -TP73 and Breast Cancer
9
SUZ12 17q11.2 CHET9, JJAZ1 -SUZ12 and Breast Cancer
9
PMAIP1 18q21.32 APR, NOXA -PMAIP1 and Breast Cancer
9
AKR1C2 10p15-p14 DD, DD2, TDD, BABP, DD-2, DDH2, HBAB, HAKRD, MCDR2, SRXY8, DD/BABP, AKR1C-pseudo -AKR1C2 and Breast Cancer
9
GPC3 Xq26.1 SGB, DGSX, MXR7, SDYS, SGBS, OCI-5, SGBS1, GTR2-2 -GPC3 and Breast Cancer
9
L1CAM Xq28 S10, HSAS, MASA, MIC5, SPG1, CAML1, CD171, HSAS1, N-CAML1, NCAM-L1, N-CAM-L1 -L1CAM and Breast Cancer
8
IL17C 16q24 CX2, IL-17C -IL17C and Breast Cancer
8
POT1 7q31.33 CMM10, HPOT1 -POT1 and Breast Cancer
8
CDH2 18q11.2 CDHN, NCAD, CD325, CDw325 -CDH2 and Breast Cancer
8
SOX11 2p25 MRD27 -SOX11 and Breast Cancer
8
LOXL2 8p21.3 LOR2, WS9-14 -LOXL2 and Breast Cancer
8
INSR 19p13.3-p13.2 HHF5, CD220 -INSR and Breast Cancer
8
KLK14 19q13.3-q13.4 KLK-L6 -KLK14 and Breast Cancer
8
HBEGF 5q23 DTR, DTS, DTSF, HEGFL -HBEGF and Breast Cancer
8
B2M 15q21.1 -B2M and Breast Cancer
8
KPNA2 17q24.2 QIP2, RCH1, IPOA1, SRP1alpha -KPNA2 and Breast Cancer
8
SKP1 5q31 OCP2, p19A, EMC19, SKP1A, OCP-II, TCEB1L -SKP1 and Breast Cancer
8
EFNB2 13q33 HTKL, EPLG5, Htk-L, LERK5 -EFNB2 expression in Breast Cancer
8
ERCC5 13q33 XPG, UVDR, XPGC, COFS3, ERCM2, ERCC5-201 -ERCC5 and Breast Cancer
8
CRY2 11p11.2 HCRY2, PHLL2 -CRY2 and Breast Cancer
8
MIR127 14q32.2 MIRN127, mir-127, miRNA127 -MicroRNA miR-127 and Breast Cancer
8
HOXA1 7p15.3 BSAS, HOX1, HOX1F -HOXA1 and Breast Cancer
8
XIST Xq13.2 SXI1, swd66, DXS1089, DXS399E, LINC00001, NCRNA00001 -XIST and Breast Cancer
8
WNT10B 12q13 SHFM6, WNT-12 -WNT10B and Breast Cancer
8
SUMO1 2q33 DAP1, GMP1, PIC1, SMT3, UBL1, OFC10, SENP2, SMT3C, SMT3H3 -SUMO1 and Breast Cancer
8
RPA1 17p13.3 HSSB, RF-A, RP-A, REPA1, RPA70, MST075 -RPA1 and Breast Cancer
8
RICTOR 5p13.1 PIA, AVO3, hAVO3 -RICTOR and Breast Cancer
8
EPHB6 7q33-q35 HEP -EPHB6 and Breast Cancer
8
IKBKE 1q32.1 IKKE, IKKI, IKK-E, IKK-i -IKBKE and Breast Cancer
8
SUV39H1 Xp11.23 MG44, KMT1A, SUV39H, H3-K9-HMTase 1 -SUV39H1 and Breast Cancer
8
WRN 8p12 RECQ3, RECQL2, RECQL3 -WRN and Breast Cancer
8
BMP7 20q13 OP-1 -BMP7 and Breast Cancer
8
BUB3 10q26 BUB3L, hBUB3 -BUB3 and Breast Cancer
8
POSTN 13q13.3 PN, OSF2, OSF-2, PDLPOSTN, periostin -POSTN and Breast Cancer
8
TEP1 14q11.2 TP1, TLP1, p240, TROVE1, VAULT2 -TEP1 and Breast Cancer
8
MSX2 5q35.2 FPP, MSH, PFM, CRS2, HOX8, PFM1 -MSX2 and Breast Cancer
8
DUSP1 5q34 HVH1, MKP1, CL100, MKP-1, PTPN10 -DUSP1 and Breast Cancer
8
CBFA2T3 16q24 ETO2, MTG16, MTGR2, ZMYND4 -CBFA2T3 and Breast Cancer
8
ADAM9 8p11.22 MCMP, MDC9, CORD9, Mltng -ADAM9 and Breast Cancer
8
GAB2 11q14.1 -GAB2 and Breast Cancer
8
CASP10 2q33-q34 MCH4, ALPS2, FLICE2 -CASP10 and Breast Cancer
8
BNIP3L 8p21 NIX, BNIP3a -BNIP3L and Breast Cancer
8
CASP1 11q22.3 ICE, P45, IL1BC -CASP1 and Breast Cancer
8
TJP1 15q13 ZO-1 -TJP1 and Breast Cancer
8
NQO2 6p25.2 QR2, DHQV, DIA6, NMOR2 -NQO2 and Breast Cancer
8
XBP1 22q12.1 XBP2, TREB5, XBP-1, TREB-5 -XBP1 and Breast Cancer
8
BIN1 2q14 AMPH2, AMPHL, SH3P9 -BIN1 and Breast Cancer
8
TFPI 2q32 EPI, TFI, LACI, TFPI1 -TFPI and Breast Cancer
8
CUL1 7q36.1 -CUL1 and Breast Cancer
8
S100A9 1q21 MIF, NIF, P14, CAGB, CFAG, CGLB, L1AG, LIAG, MRP14, 60B8AG, MAC387 -S100A9 and Breast Cancer
8
KDM5B 1q32.1 CT31, PLU1, PUT1, PLU-1, JARID1B, PPP1R98, RBBP2H1A -KDM5B and Breast Cancer
8
KDM1A 1p36.12 AOF2, KDM1, LSD1, BHC110 -KDM1A and Breast Cancer
8
ADRB2 5q31-q32 BAR, B2AR, ADRBR, ADRB2R, BETA2AR -ADRB2 and Breast Cancer
8
KEAP1 19p13.2 INrf2, KLHL19 -KEAP1 and Breast Cancer
8
LATS1 6q25.1 wts, WARTS -LATS1 and Breast Cancer
8
LYN 8q13 JTK8, p53Lyn, p56Lyn -LYN and Breast Cancer
8
AXL 19q13.1 ARK, UFO, JTK11, Tyro7 -AXL and Breast Cancer
8
ATG7 3p25.3 GSA7, APG7L, APG7-LIKE -ATG7 and Breast Cancer
8
PTPRQ 12q21.2 DFNB84, DFNB84A, PTPGMC1, R-PTP-Q -PTPRQ and Breast Cancer
8
SREBF1 17p11.2 SREBP1, bHLHd1, SREBP-1c -SREBF1 and Breast Cancer
8
CD74 5q32 II, DHLAG, HLADG, Ia-GAMMA -CD74 and Breast Cancer
8
CDC6 17q21.3 CDC18L, HsCDC6, HsCDC18 -CDC6 and Breast Cancer
8
KLK6 19q13.3 hK6, Bssp, Klk7, SP59, PRSS9, PRSS18 -KLK6 and Breast Cancer
8
PRINS 10p12.1 NCRNA00074 -PRINS and Breast Cancer
8
DDX5 17q21 p68, HLR1, G17P1, HUMP68 -DDX5 and Breast Cancer
8
CDH3 16q22.1 CDHP, HJMD, PCAD -CDH3 and Breast Cancer
8
ATF2 2q32 HB16, CREB2, TREB7, CREB-2, CRE-BP1 -ATF2 and Breast Cancer
8
CXCR2 2q35 CD182, IL8R2, IL8RA, IL8RB, CMKAR2, CDw128b -CXCR2 and Breast Cancer
8
NR5A2 1q32.1 B1F, CPF, FTF, B1F2, LRH1, LRH-1, FTZ-F1, hB1F-2, FTZ-F1beta -NR5A2 and Breast Cancer
8
BUB1B 15q15 MVA1, SSK1, BUBR1, Bub1A, MAD3L, hBUBR1, BUB1beta -BUB1B and Breast Cancer
8
ALDH3A1 17p11.2 ALDH3, ALDHIII -ALDH3A1 and Breast Cancer
7
UHRF1 19p13.3 Np95, hNP95, ICBP90, RNF106, hUHRF1, huNp95 -UHRF1 and Breast Cancer
7
TNFSF15 9q32 TL1, TL1A, VEGI, VEGI192A -TNFSF15 and Breast Cancer
7
IL6ST 5q11.2 CD130, GP130, CDW130, IL-6RB -IL6ST and Breast Cancer
7
HMMR 5q34 CD168, IHABP, RHAMM -HMMR and Breast Cancer
7
AKR1C1 10p15-p14 C9, DD1, DDH, DDH1, H-37, HBAB, MBAB, HAKRC, DD1/DD2, 2-ALPHA-HSD, 20-ALPHA-HSD -AKR1C1 and Breast Cancer
7
FGF10 5p13-p12 -FGF10 and Breast Cancer
7
ADAM17 2p25 CSVP, TACE, NISBD, ADAM18, CD156B, NISBD1 -ADAM17 and Breast Cancer
7
CXCL13 4q21 BLC, BCA1, ANGIE, BCA-1, BLR1L, ANGIE2, SCYB13 -CXCL13 and Breast Cancer
7
PRC1 15q26.1 ASE1 -PRC1 and Breast Cancer
7
MAP2K2 19p13.3 CFC4, MEK2, MKK2, MAPKK2, PRKMK2 -MAP2K2 and Breast Cancer
7
DRD2 11q23.2 D2R, D2DR -DRD2 and Breast Cancer
7
PAEP 9q34 GD, GdA, GdF, GdS, PEP, PAEG, PP14 -PAEP and Breast Cancer
7
LDHA 11p15.1 LDHM, GSD11, PIG19, HEL-S-133P -LDHA and Breast Cancer
7
DACH1 13q22 DACH -DACH1 and Breast Cancer
7
YY1AP1 1q22 YAP, HCCA1, HCCA2, YY1AP -YY1AP1 and Breast Cancer
7
NCOA2 8q13.3 SRC2, TIF2, GRIP1, KAT13C, NCoA-2, bHLHe75 -NCOA2 and Breast Cancer
7
IL13 5q31 P600, IL-13 -IL13 and Breast Cancer
7
STC1 8p21.2 STC -STC1 and Breast Cancer
7
KRT18 12q13 K18, CK-18, CYK18 -KRT18 and Breast Cancer
7
PYGM 11q13.1 -PYGM and Breast Cancer
7
S100P 4p16 MIG9 -S100P and Breast Cancer
7
STAT6 12q13 STAT6B, STAT6C, D12S1644, IL-4-STAT -STAT6 and Breast Cancer
7
MICA 6p21.33 MIC-A, PERB11.1 -MICA and Breast Cancer
7
TRAF6 11p12 RNF85, MGC:3310 -TRAF6 and Breast Cancer
7
PCGF2 17q12 MEL-18, RNF110, ZNF144 -PCGF2 and Breast Cancer
7
MAML1 5q35 Mam1, Mam-1 -MAML1 and Breast Cancer
7
GATA4 8p23.1-p22 TOF, ASD2, VSD1, TACHD -GATA4 and Breast Cancer
7
FOSL1 11q13.1 FRA, FRA1, fra-1 -FOSL1 and Breast Cancer
7
ZFP36 19q13.1 TTP, G0S24, GOS24, TIS11, NUP475, zfp-36, RNF162A -ZFP36 and Breast Cancer
7
PON1 7q21.3 ESA, PON, MVCD5 -PON1 and Breast Cancer
7
MIF 22q11.23 GIF, GLIF, MMIF -MIF and Breast Cancer
7
ARNTL 11p15.3 TIC, JAP3, MOP3, BMAL1, PASD3, BMAL1c, bHLHe5 -ARNTL and Breast Cancer
7
BMPR2 2q33-q34 BMR2, PPH1, BMPR3, BRK-3, POVD1, T-ALK, BMPR-II -BMPR2 and Breast Cancer
7
DPYD 1p22 DHP, DPD, DHPDHASE -DPYD and Breast Cancer
7
MYOD1 11p15.1 PUM, MYF3, MYOD, bHLHc1 -MYOD1 and Breast Cancer
7
HSPA8 11q24.1 LAP1, HSC54, HSC70, HSC71, HSP71, HSP73, LAP-1, NIP71, HEL-33, HSPA10, HEL-S-72p -HSPA8 and Breast Cancer
7
ADIPOR2 12p13.31 PAQR2, ACDCR2 -ADIPOR2 and Breast Cancer
7
NEDD4 15q RPF1, NEDD4-1 -NEDD4 and Breast Cancer
7
GSTM3 1p13.3 GST5, GSTB, GTM3, GSTM3-3 -GSTM3 and Breast Cancer
7
PTPRH 19q13.4 SAP1, R-PTP-H -PTPRH and Breast Cancer
7
NR4A1 12q13 HMR, N10, TR3, NP10, GFRP1, NAK-1, NGFIB, NUR77 -NR4A1 and Breast Cancer
7
ADIPOQ 3q27 ACDC, ADPN, APM1, APM-1, GBP28, ACRP30, ADIPQTL1 -ADIPOQ and Breast Cancer
7
IL1A 2q14 IL1, IL-1A, IL1F1, IL1-ALPHA -IL1A and Breast Cancer
7
IL2 4q26-q27 IL-2, TCGF, lymphokine -IL2 and Breast Cancer
7
NAV1 1q32.3 POMFIL3, UNC53H1, STEERIN1 -NAV1 and Breast Cancer
7
IQGAP1 15q26.1 SAR1, p195, HUMORFA01 -IQGAP1 and Breast Cancer
7
TERF2 16q22.1 TRF2, TRBF2 -TERF2 and Breast Cancer
7
EPHB4 7q22 HTK, MYK1, TYRO11 -EPHB4 and Breast Cancer
7
NEFL 8p21 NFL, NF-L, NF68, CMT1F, CMT2E, PPP1R110 -NEFL and Breast Cancer
7
EPOR 19p13.3-p13.2 EPO-R -EPOR and Breast Cancer
7
E2F5 8q21.2 E2F-5 -E2F5 and Breast Cancer
7
HDAC4 2q37.3 HD4, AHO3, BDMR, HDACA, HA6116, HDAC-4, HDAC-A -HDAC4 and Breast Cancer
7
CMBL 5p15.2 JS-1 -CMBL and Breast Cancer
6
LYVE1 11p15.4 HAR, XLKD1, LYVE-1, CRSBP-1 -LYVE1 and Breast Cancer
6
ITGA4 2q31.3 IA4, CD49D -ITGA4 and Breast Cancer
6
NGFR 17q21-q22 CD271, p75NTR, TNFRSF16, p75(NTR), Gp80-LNGFR -NGFR and Breast Cancer
6
ADAM10 15q22 RAK, kuz, AD10, AD18, MADM, CD156c, HsT18717 -ADAM10 and Breast Cancer
6
WNT4 1p36.23-p35.1 WNT-4, SERKAL -WNT4 and Breast Cancer
6
IL4 5q31.1 BSF1, IL-4, BCGF1, BSF-1, BCGF-1 -IL4 and Breast Cancer
6
TXNIP 1q21.1 THIF, VDUP1, HHCPA78, EST01027 -TXNIP and Breast Cancer
6
CLDN7 17p13.1 CLDN-7, CEPTRL2, CPETRL2, Hs.84359, claudin-1 -CLDN7 and Breast Cancer
6
CHUK 10q24-q25 IKK1, IKKA, IKBKA, TCF16, NFKBIKA, IKK-alpha -CHUK and Breast Cancer
6
WNT2 7q31.2 IRP, INT1L1 -WNT2 and Breast Cancer
6
NUMB 14q24.3 S171, C14orf41, c14_5527 -NUMB and Breast Cancer
6
ABCC3 17q22 MLP2, MRP3, ABC31, MOAT-D, cMOAT2, EST90757 -ABCC3 and Breast Cancer
6
ABCC5 3q27 MRP5, SMRP, ABC33, MOATC, MOAT-C, pABC11, EST277145 -ABCC5 and Breast Cancer
6
ST7 7q31.2 HELG, RAY1, SEN4, TSG7, ETS7q, FAM4A, FAM4A1 -ST7 and Breast Cancer
6
MCM2 3q21 BM28, CCNL1, CDCL1, cdc19, D3S3194, MITOTIN -MCM2 and Breast Cancer
6
XRCC6 22q13.2 ML8, KU70, TLAA, CTC75, CTCBF, G22P1 -XRCC6 and Breast Cancer
6
CD46 1q32 MCP, TLX, AHUS2, MIC10, TRA2.10 -CD46 and Breast Cancer
6
ITGA6 2q31.1 CD49f, VLA-6, ITGA6B -ITGA6 and Breast Cancer
6
TPX2 20q11.2 DIL2, p100, DIL-2, HCTP4, FLS353, HCA519, REPP86, C20orf1, C20orf2, GD:C20orf1 -TPX2 and Breast Cancer
6
ROBO1 3p12 SAX3, DUTT1 -ROBO1 and Breast Cancer
6
WISP1 8q24.22 CCN4, WISP1c, WISP1i, WISP1tc -WISP1 and Breast Cancer
6
SLIT2 4p15.2 SLIL3, Slit-2 -SLIT2 and Breast Cancer
6
PMP22 17p12 DSS, HNPP, CMT1A, CMT1E, GAS-3, Sp110, HMSNIA -PMP22 and Breast Cancer
6
CYBA 16q24 p22-PHOX -CYBA and Breast Cancer
6
DDR1 6p21.3 CAK, DDR, NEP, HGK2, PTK3, RTK6, TRKE, CD167, EDDR1, MCK10, NTRK4, PTK3A -DDR1 and Breast Cancer
6
NUMA1 11q13.4 NUMA, NMP-22 -NUMA1 and Breast Cancer
6
ARL11 13q14.2 ARLTS1 -ARL11 and Breast Cancer
6
NBR1 17q21.31 IAI3B, M17S2, MIG19, 1A1-3B -NBR1 and Breast Cancer
6
DMBT1 10q26.13 GP340, muclin -DMBT1 and Breast Cancer
6
KRT8 12q13 K8, KO, CK8, CK-8, CYK8, K2C8, CARD2 -KRT8 and Breast Cancer
6
NOD2 16q21 CD, ACUG, BLAU, IBD1, NLRC2, NOD2B, CARD15, CLR16.3, PSORAS1 -NOD2 and Breast Cancer
6
KLK5 19q13.33 SCTE, KLKL2, KLK-L2 -KLK5 and Breast Cancer
6
PTPN1 20q13.1-q13.2 PTP1B -PTPN1 and Breast Cancer
6
PTPRG 3p21-p14 PTPG, HPTPG, RPTPG, R-PTP-GAMMA -PTPRG and Breast Cancer
6
TACR1 2p12 SPR, NK1R, NKIR, TAC1R -TACR1 and Breast Cancer
6
TNFAIP3 6q23 A20, OTUD7C, TNFA1P2 -TNFAIP3 and Breast Cancer
6
FOSB 19q13.32 AP-1, G0S3, GOS3, GOSB -FOSB and Breast Cancer
6
HNRNPA2B1 7p15 RNPA2, HNRPA2, HNRPB1, SNRPB1, HNRNPA2, HNRNPB1, IBMPFD2, HNRPA2B1 -HNRNPA2B1 and Breast Cancer
6
PER1 17p13.1 PER, hPER, RIGUI -PER1 and Breast Cancer
6
CCNA1 13q12.3-q13 CT146 -CCNA1 and Breast Cancer
6
GDNF 5p13.1-p12 ATF1, ATF2, HSCR3, HFB1-GDNF -GDNF and Breast Cancer
6
ADH1B 4q23 ADH2, HEL-S-117 -ADH1B and Breast Cancer
6
MIR107 10q23.31 MIRN107, miR-107 -MicroRNA mir-107 and Breast Cancer
6
LTA 6p21.3 LT, TNFB, TNFSF1 -LTA and Breast Cancer
6
CD163 12p13.3 M130, MM130 -CD163 and Breast Cancer
6
BANP 16q24 BEND1, SMAR1, SMARBP1 -BANP and Breast Cancer
6
SIN3A 15q24.2 -SIN3A and Breast Cancer
6
WHSC1L1 8p11.2 NSD3, pp14328 -WHSC1L1 and Breast Cancer
6
BCAS1 20q13.2 AIBC1, NABC1 -BCAS1 and Breast Cancer
6
PER3 1p36.23 GIG13 -PER3 and Breast Cancer
6
PRDM2 1p36.21 RIZ, KMT8, RIZ1, RIZ2, MTB-ZF, HUMHOXY1 -PRDM2 and Breast Cancer
6
KISS1R 19p13.3 HH8, CPPB1, GPR54, AXOR12, KISS-1R, HOT7T175 -KISS1R and Breast Cancer
6
NEDD9 6p24.2 CAS2, CASL, HEF1, CAS-L, CASS2 -NEDD9 and Breast Cancer
6
EEF1A2 20q13.3 HS1, STN, EF1A, STNL, EEF1AL, EF-1-alpha-2 -EEF1A2 and Breast Cancer
6
FGF7 15q21.2 KGF, HBGF-7 -FGF7 and Breast Cancer
6
TRIO 5p15.2 tgat, ARHGEF23 -TRIO and Breast Cancer
6
IL15 4q31 IL-15 -IL15 and Breast Cancer
6
FGF19 11q13.3 -FGF19 and Breast Cancer
6
ETV6 12p13 TEL, THC5, TEL/ABL Translocation
-t(12;15)(p13;q25) ETV6-NTRK3 in Breast Cancer
6
TNKS 8p23.1 TIN1, ARTD5, PARPL, TINF1, TNKS1, pART5, PARP5A, PARP-5a -TNKS and Breast Cancer
6
PTPRF 1p34 LAR, BNAH2 -PTPRF and Breast Cancer
6
EREG 4q13.3 ER, Ep, EPR -EREG and Breast Cancer
6
SLC19A2 1q23.3 TC1, THT1, TRMA, THMD1, THTR1 -SLC19A2 and Breast Cancer
6
CA12 15q22 CAXII, HsT18816 -CA12 and Breast Cancer
6
CYP11A1 15q23-q24 CYP11A, CYPXIA1, P450SCC -CYP11A1 and Breast Cancer
6
TNFRSF10C 8p22-p21 LIT, DCR1, TRID, CD263, TRAILR3, TRAIL-R3, DCR1-TNFR -TNFRSF10C and Breast Cancer
6
CCR2 3p21.31 CKR2, CCR-2, CCR2A, CCR2B, CD192, CKR2A, CKR2B, CMKBR2, MCP-1-R, CC-CKR-2 -CCR2 and Breast Cancer
6
EBAG9 8q23 EB9, PDAF -EBAG9 and Breast Cancer
6
SOX17 8q11.23 VUR3 -SOX17 and Breast Cancer
6
RAC3 17q25.3 -RAC3 and Breast Cancer
6
FUT4 11q21 LeX, CD15, ELFT, FCT3A, FUTIV, SSEA-1, FUC-TIV -FUT4 and Breast Cancer
6
PLAT 8p12 TPA, T-PA -PLAT and Breast Cancer
6
NDRG2 14q11.2 SYLD -NDRG2 and Breast Cancer
6
CUL3 2q36.2 CUL-3, PHA2E -CUL3 and Breast Cancer
6
DUSP4 8p12-p11 TYP, HVH2, MKP2, MKP-2 -DUSP4 and Breast Cancer
6
TLR1 4p14 TIL, CD281, rsc786, TIL. LPRS5 -TLR1 and Breast Cancer
6
SKI 1p36.33 SGS, SKV -SKI and Breast Cancer
6
PTPRC 1q31-q32 LCA, LY5, B220, CD45, L-CA, T200, CD45R, GP180 -PTPRC and Breast Cancer
6
LGALS1 22q13.1 GBP, GAL1 -LGALS1 and Breast Cancer
6
PTPRJ 11p11.2 DEP1, SCC1, CD148, HPTPeta, R-PTP-ETA -PTPRJ and Breast Cancer
6
MMP8 11q22.2 HNC, CLG1, MMP-8, PMNL-CL -MMP8 and Breast Cancer
6
HOXA10 7p15.2 PL, HOX1, HOX1H, HOX1.8 -HOXA10 and Breast Cancer
6
CD36 7q11.2 FAT, GP4, GP3B, GPIV, CHDS7, PASIV, SCARB3, BDPLT10 -CD36 and Breast Cancer
6
TLR2 4q32 TIL4, CD282 -TLR2 and Breast Cancer
6
CEACAM6 19q13.2 NCA, CEAL, CD66c -CEACAM6 and Breast Cancer
6
SOCS2 12q CIS2, SSI2, Cish2, SSI-2, SOCS-2, STATI2 -SOCS2 and Breast Cancer
6
TANK 2q24.2 ITRAF, TRAF2, I-TRAF -TANK and Breast Cancer
6
SQSTM1 5q35 p60, p62, A170, OSIL, PDB3, ZIP3, p62B -SQSTM1 and Breast Cancer
6
PGK1 Xq13.3 PGKA, MIG10, HEL-S-68p -PGK1 and Breast Cancer
6
LRP1 12q13.3 APR, LRP, A2MR, CD91, APOER, LRP1A, TGFBR5, IGFBP3R -LRP1 and Breast Cancer
5
RARRES3 11q12.3 RIG1, TIG3, HRSL4, HRASLS4, PLA1/2-3 -RARRES3 and Breast Cancer
5
GAS6 13q34 AXSF, AXLLG -GAS6 and Breast Cancer
5
DKC1 Xq28 DKC, CBF5, DKCX, NAP57, NOLA4, XAP101 -DKC1 and Breast Cancer
5
EGLN1 1q42.1 HPH2, PHD2, SM20, ECYT3, HALAH, HPH-2, HIFPH2, ZMYND6, C1orf12, HIF-PH2 -EGLN1 and Breast Cancer
5
CXCL14 5q31 KEC, KS1, BMAC, BRAK, NJAC, MIP2G, MIP-2g, SCYB14 -CXCL14 and Breast Cancer
5
CCL21 9p13 ECL, SLC, CKb9, TCA4, 6Ckine, SCYA21 -CCL21 and Breast Cancer
5
LASP1 17q11-q21.3 MLN50, Lasp-1 -LASP1 and Breast Cancer
5
MIRLET7G 3p21.1 LET7G, let-7g, MIRNLET7G, hsa-let-7g -MicroRNA let-7g and Breast Cancer
5
GNRHR 4q21.2 HH7, GRHR, LRHR, LHRHR, GNRHR1 -GNRHR and Breast Cancer
5
FABP7 6q22-q23 MRG, BLBP, FABPB, B-FABP, LTR2-FABP7 -FABP7 and Breast Cancer
5
MVP 16p11.2 LRP, VAULT1 -MVP and Breast Cancer
5
POU1F1 3p11 PIT1, CPHD1, GHF-1, Pit-1, POU1F1a -POU1F1 and Breast Cancer
5
MAGEA4 Xq28 CT1.4, MAGE4, MAGE4A, MAGE4B, MAGE-41, MAGE-X2 -MAGEA4 and Breast Cancer
5
APOB 2p24-p23 FLDB, LDLCQ4 -APOB and Breast Cancer
5
FRZB 2q32.1 FRE, OS1, FZRB, hFIZ, FRITZ, FRP-3, FRZB1, SFRP3, SRFP3, FRZB-1, FRZB-PEN -FRZB and Breast Cancer
5
ING4 12p13.31 my036, p29ING4 -ING4 and Breast Cancer
5
TFRC 3q29 T9, TR, TFR, p90, CD71, TFR1, TRFR -TFRC and Breast Cancer
5
CXCR1 2q35 C-C, CD128, CD181, CKR-1, IL8R1, IL8RA, CMKAR1, IL8RBA, CDw128a, C-C-CKR-1 -CXCR1 and Breast Cancer
5
DDIT4 10q22.1 Dig2, REDD1, REDD-1 -DDIT4 and Breast Cancer
5
SPHK1 17q25.2 SPHK -SPHK1 and Breast Cancer
5
CCL20 2q36.3 CKb4, LARC, ST38, MIP3A, Exodus, MIP-3a, SCYA20, MIP-3-alpha -CCL20 and Breast Cancer
5
PRDX1 1p34.1 PAG, PAGA, PAGB, PRX1, PRXI, MSP23, NKEFA, TDPX2, NKEF-A -PRDX1 and Breast Cancer
5
SSTR5 16p13.3 SS-5-R -SSTR5 and Breast Cancer
5
SAT2 17p13.1 SSAT2 -SAT2 and Breast Cancer
5
MAD1L1 7p22 MAD1, PIG9, TP53I9, TXBP181 -MAD1L1 and Breast Cancer
5
SKIL 3q26 SNO, SnoA, SnoI, SnoN -SKIL and Breast Cancer
5
TXNRD1 12q23-q24.1 TR, TR1, TXNR, TRXR1, GRIM-12 -TXNRD1 and Breast Cancer
5
SULF2 20q13.12 HSULF-2 -SULF2 and Breast Cancer
5
PDPK1 16p13.3 PDK1, PDPK2, PDPK2P, PRO0461 -PDPK1 and Breast Cancer
5
CDK7 5q12.1 CAK1, HCAK, MO15, STK1, CDKN7, p39MO15 -CDK7 and Breast Cancer
5
REST 4q12 XBR, NRSF -REST and Breast Cancer
5
MUC5B 11p15.5 MG1, MUC5, MUC9, MUC-5B -MUC5B and Breast Cancer
5
CCR4 3p24 CKR4, K5-5, CD194, CMKBR4, ChemR13, CC-CKR-4, HGCN:14099 -CCR4 and Breast Cancer
5
CKS1B 1q21.2 CKS1, ckshs1, PNAS-16, PNAS-18 -CKS1B and Breast Cancer
5
CTBP1 4p16 BARS -CTBP1 and Breast Cancer
5
ST14 11q24.3 HAI, MTSP1, SNC19, ARCI11, MT-SP1, PRSS14, TADG15, TMPRSS14 -ST14 and Breast Cancer
5
CCNG2 4q21.1 -CCNG2 and Breast Cancer
5
SFRP5 10q24.1 SARP3 -SFRP5 and Breast Cancer
5
POLD1 19q13.3 CDC2, MDPL, POLD, CRCS10 -POLD1 and Breast Cancer
5
CALU 7q32.1 -CALU and Breast Cancer
5
SCRIB 8q24.3 CRIB1, SCRB1, SCRIB1, Vartul -SCRIB and Breast Cancer
5
HYAL1 3p21.31 MPS9, NAT6, LUCA1, HYAL-1 -HYAL1 and Breast Cancer
5
GSTO2 10q25.1 GSTO 2-2, bA127L20.1 -GSTO2 and Breast Cancer
5
UGT2B15 4q13 HLUG4, UGT2B8, UDPGTH3, UDPGT 2B8, UDPGT2B15 -UGT2B15 and Breast Cancer
5
CXCR5 11q23.3 BLR1, CD185, MDR15 -CXCR5 and Breast Cancer
5
PARK7 1p36.23 DJ1, DJ-1, HEL-S-67p -PARK7 and Breast Cancer
5
CASP4 11q22.3 TX, Mih1, ICH-2, Mih1/TX, ICEREL-II, ICE(rel)II -CASP4 and Breast Cancer
5
LRP6 12p13.2 ADCAD2 -LRP6 and Breast Cancer
5
TPM1 15q22.1 CMH3, TMSA, CMD1Y, LVNC9, C15orf13, HTM-alpha -TPM1 and Breast Cancer
5
TAGLN 11q23.3 SM22, SMCC, TAGLN1, WS3-10 -TAGLN and Breast Cancer
5
AMFR 16q21 GP78, RNF45 -AMFR and Breast Cancer
5
MAPK14 6p21.3-p21.2 RK, p38, CSBP, EXIP, Mxi2, CSBP1, CSBP2, CSPB1, PRKM14, PRKM15, SAPK2A, p38ALPHA -MAPK14 and Breast Cancer
5
MTHFD1 14q24 MTHFC, MTHFD -MTHFD1 and Breast Cancer
5
TPD52L1 6q22-q23 D53, hD53 -TPD52L1 and Breast Cancer
5
ACTA2 10q23.3 AAT6, ACTSA, MYMY5 -ACTA2 and Breast Cancer
5
PPP2R1B 11q23.1 PR65B, PP2A-Abeta -PPP2R1B and Breast Cancer
5
GSTO1 10q25.1 P28, SPG-R, GSTO 1-1, GSTTLp28, HEL-S-21 -GSTO1 and Breast Cancer
5
IER3 6p21.3 DIF2, IEX1, PRG1, DIF-2, GLY96, IEX-1, IEX-1L -IER3 and Breast Cancer
5
SEMA3B 3p21.3 SemA, SEMA5, SEMAA, semaV, LUCA-1 -SEMA3B and Breast Cancer
5
CD151 11p15.5 GP27, MER2, RAPH, SFA1, PETA-3, TSPAN24 -CD151 and Breast Cancer
5
PINX1 8p23 LPTL, LPTS -PINX1 and Breast Cancer
5
USF1 1q22-q23 UEF, FCHL, MLTF, FCHL1, MLTFI, HYPLIP1, bHLHb11 -USF1 and Breast Cancer
5
IGFBP7 4q12 AGM, PSF, TAF, FSTL2, IBP-7, MAC25, IGFBP-7, RAMSVPS, IGFBP-7v, IGFBPRP1 -IGFBP7 and Breast Cancer
5
KLLN 10q23 CWS4, KILLIN -KLLN and Breast Cancer
5
SHMT1 17p11.2 SHMT, CSHMT -SHMT1 and Breast Cancer
5
LAPTM4B 8q22.1 LC27, LAPTM4beta -LAPTM4B and Breast Cancer
5
TP53INP1 8q22 SIP, Teap, p53DINP1, TP53DINP1, TP53INP1A, TP53INP1B -TP53INP1 and Breast Cancer
5
DLL4 15q14 hdelta2 -DLL4 and Breast Cancer
5
TRADD 16q22 Hs.89862 -TRADD and Breast Cancer
5
TYRO3 15q15 BYK, Dtk, RSE, Rek, Sky, Tif, Etk-2 -TYRO3 and Breast Cancer
5
LRIG1 3p14 LIG1, LIG-1 -LRIG1 and Breast Cancer
5
S100A2 1q21 CAN19, S100L -S100A2 and Breast Cancer
5
PTMS 12p13 ParaT -PTMS and Breast Cancer
5
DUSP6 12q22-q23 HH19, MKP3, PYST1 -DUSP6 and Breast Cancer
5
STRADA 17q23.3 LYK5, PMSE, Stlk, STRAD, NY-BR-96 -STRADA and Breast Cancer
5
SULF1 8q13.2 SULF-1, HSULF-1 -SULF1 and Breast Cancer
5
HIPK2 7q34 PRO0593 -HIPK2 and Breast Cancer
5
ISG15 1p36.33 G1P2, IP17, UCRP, IFI15, IMD38, hUCRP -ISG15 and Breast Cancer
5
KLK4 19q13.41 ARM1, EMSP, PSTS, AI2A1, EMSP1, KLK-L1, PRSS17, kallikrein -KLK4 and Breast Cancer
5
WNT11 11q13.5 HWNT11 -WNT11 and Breast Cancer
5
ANGPTL4 19p13.3 NL2, ARP4, FIAF, HARP, PGAR, HFARP, TGQTL, UNQ171, pp1158, ANGPTL2 -ANGPTL4 and Breast Cancer
5
ALOX5 10q11.2 5-LO, 5LPG, LOG5, 5-LOX -ALOX5 and Breast Cancer
5
RAG2 11p12 RAG-2 -RAG2 and Breast Cancer
5
FHL2 2q12.2 DRAL, AAG11, FHL-2, SLIM3, SLIM-3 -FHL2 and Breast Cancer
5
PVT1 8q24 LINC00079, NCRNA00079, onco-lncRNA-100 -PVT1 and Breast Cancer
5
LARS 5q32 LRS, LEUS, LFIS, ILFS1, LARS1, LEURS, PIG44, RNTLS, HSPC192, hr025Cl -LARS and Breast Cancer
5
RALGDS 9q34.3 RGF, RGDS, RalGEF -RALGDS and Breast Cancer
5
TBK1 12q14.1 NAK, T2K -TBK1 and Breast Cancer
5
RBX1 22q13.2 ROC1, RNF75, BA554C12.1 -RBX1 and Breast Cancer
4
CXCL9 4q21 CMK, MIG, Humig, SCYB9, crg-10 -CXCL9 and Breast Cancer
4
IFITM1 11p15.5 9-27, CD225, IFI17, LEU13, DSPA2a -IFITM1 and Breast Cancer
4
GRASP 12q13.13 TAMALIN -GRASP and Breast Cancer
4
GRM1 6q24 MGLU1, GPRC1A, MGLUR1, SCAR13, PPP1R85 -GRM1 and Breast Cancer
4
TRAF1 9q33-q34 EBI6, MGC:10353 -TRAF1 and Breast Cancer
4
MYCN 2p24.3 NMYC, ODED, MODED, N-myc, bHLHe37 -MYCN and Breast Cancer
4
KDM4C 9p24.1 GASC1, JHDM3C, JMJD2C, TDRD14C -KDM4C and Breast Cancer
4
AVPR1A 12q14.2 V1aR, AVPR1, AVPR V1a -AVPR1A and Breast Cancer
4
CASP6 4q25 MCH2 -CASP6 and Breast Cancer
4
PHIP 6q14 ndrp, BRWD2, WDR11, DCAF14 -PHIP and Breast Cancer
4
HPSE 4q21.3 HPA, HPA1, HPR1, HSE1, HPSE1 -HPSE and Breast Cancer
4
NFKBIA 14q13 IKBA, MAD-3, NFKBI -NFKBIA and Breast Cancer
4
ANO1 11q13.3 DOG1, TAOS2, ORAOV2, TMEM16A -ANO1 and Breast Cancer
4
ABCA1 9q31.1 TGD, ABC1, CERP, ABC-1, HDLDT1 -ABCA1 and Breast Cancer
4
CD69 12p13 AIM, EA1, MLR-3, CLEC2C, GP32/28, BL-AC/P26 -CD69 and Breast Cancer
4
GREM1 15q13.3 DRM, HMPS, MPSH, PIG2, CRAC1, CRCS4, DAND2, HMPS1, IHG-2, DUP15q, C15DUPq, GREMLIN, CKTSF1B1 -GREM1 and Breast Cancer
4
HOXC11 12q13.3 HOX3H -HOXC11 and Breast Cancer
4
MMP10 11q22.2 SL-2, STMY2 -MMP10 and Breast Cancer
4
KRT14 17q21.2 K14, NFJ, CK14, EBS3, EBS4 -KRT14 and Breast Cancer
4
CXCL5 4q13.3 SCYB5, ENA-78 -CXCL5 and Breast Cancer
4
ITGB2 21q22.3 LAD, CD18, MF17, MFI7, LCAMB, LFA-1, MAC-1 -ITGB2 and Breast Cancer
4
RAG1 11p12 RAG-1, RNF74 -RAG1 and Breast Cancer
4
GMNN 6p22.3 Gem -GMNN and Breast Cancer
4
MTSS1 8p22 MIM, MIMA, MIMB -MTSS1 and Breast Cancer
4
DAB2IP 9q33.1-q33.3 AIP1, AIP-1, AF9Q34, DIP1/2 -DAB2IP and Breast Cancer
4
MX1 21q22.3 MX, MxA, IFI78, IFI-78K -MX1 and Breast Cancer
4
CCNG1 5q32-q34 CCNG -CCNG1 and Breast Cancer
4
EGLN3 14q13.1 PHD3, HIFPH3, HIFP4H3 -EGLN3 and Breast Cancer
4
AQP1 7p14 CO, CHIP28, AQP-CHIP -AQP1 and Breast Cancer
4
RECQL4 8q24.3 RECQ4 -RECQL4 and Breast Cancer
4
LRP5 11q13.2 HBM, LR3, OPS, EVR1, EVR4, LRP7, OPPG, BMND1, LRP-5, OPTA1, VBCH2 -LRP5 and Breast Cancer
4
CCL3 17q12 MIP1A, SCYA3, G0S19-1, LD78ALPHA, MIP-1-alpha -CCL3 and Breast Cancer
4
FGR 1p36.2-p36.1 SRC2, c-fgr, c-src2, p55-Fgr, p58-Fgr, p55c-fgr, p58c-fgr -FGR and Breast Cancer
4
STIM1 11p15.4 GOK, TAM, TAM1, IMD10, STRMK, D11S4896E -STIM1 and Breast Cancer
4
BCL11A 2p16.1 EVI9, CTIP1, ZNF856, HBFQTL5, BCL11A-L, BCL11A-S, BCL11a-M, BCL11A-XL Amplification
Overexpression
-BCL11A Overexpression and Amplification Breast Cancer
4
GNL3 3p21.1 NS, E2IG3, NNP47, C77032 -GNL3 and Breast Cancer
4
CD276 15q23-q24 B7H3, B7-H3, B7RP-2, 4Ig-B7-H3 -CD276 and Breast Cancer
4
NOX1 Xq22 MOX1, NOH1, NOH-1, GP91-2 -NOX1 and Breast Cancer
4
MELK 9p13.2 HPK38 -MELK and Breast Cancer
4
CLDN3 7q11.23 RVP1, HRVP1, C7orf1, CPE-R2, CPETR2 -CLDN3 and Breast Cancer
4
CD59 11p13 1F5, EJ16, EJ30, EL32, G344, MIN1, MIN2, MIN3, MIRL, HRF20, MACIF, MEM43, MIC11, MSK21, 16.3A5, HRF-20, MAC-IP, p18-20 -CD59 and Breast Cancer
4
SLC9A1 1p36.1-p35 APNH, NHE1, LIKNS, NHE-1, PPP1R143 -SLC9A1 and Breast Cancer
4
BTG1 12q22 -BTG1 and Breast Cancer
4
THRA 17q11.2 AR7, EAR7, ERBA, CHNG6, ERBA1, NR1A1, THRA1, THRA2, ERB-T-1, c-ERBA-1 -THRA and Breast Cancer
4
MKL1 22q13 MAL, BSAC, MRTF-A -MKL1 and Breast Cancer
4
SNRPN 15q11.2 SMN, PWCR, SM-D, sm-N, RT-LI, HCERN3, SNRNP-N, SNURF-SNRPN -SNRPN and Breast Cancer
4
AVPR1B 1q32 AVPR3 -AVPR1B and Breast Cancer
4
GNB2L1 5q35.3 H12.3, HLC-7, PIG21, RACK1, Gnb2-rs1 -GNB2L1 and Breast Cancer
4
FLNC 7q32-q35 ABPA, ABPL, FLN2, MFM5, MPD4, ABP-280, ABP280A -FLNC and Breast Cancer
4
BCL3 19q13.32 BCL4, D19S37 -BCL3 and Breast Cancer
4
CXCL16 17p13 SRPSOX, CXCLG16, SR-PSOX -CXCL16 and Breast Cancer
4
HYAL2 3p21.3 LUCA2 -HYAL2 and Breast Cancer
4
CDK9 9q34.1 TAK, C-2k, CTK1, CDC2L4, PITALRE -CDK9 and Breast Cancer
4
NFATC2 20q13.2 NFAT1, NFATP -NFATC2 and Breast Cancer
4
PRKCD 3p21.31 MAY1, PKCD, ALPS3, CVID9, nPKC-delta -PRKCD and Breast Cancer
4
IL6R 1q21 IL6Q, gp80, CD126, IL6RA, IL6RQ, IL-6RA, IL-6R-1 -IL6R and Breast Cancer
4
CTSL 9q21.33 MEP, CATL, CTSL1 -CTSL1 and Breast Cancer
4
LZTS1 8p22 F37, FEZ1 -LZTS1 and Breast Cancer
4
PPIA 7p13 CYPA, CYPH, HEL-S-69p -PPIA and Breast Cancer
4
SMPD1 11p15.4 ASM, NPD, ASMASE -SMPD1 and Breast Cancer
4
TBX21 17q21.32 TBET, T-PET, T-bet, TBLYM -TBX21 and Breast Cancer
4
SSTR1 14q13 SS1R, SS1-R, SRIF-2, SS-1-R -SSTR1 and Breast Cancer
4
ARID4A 14q23.1 RBP1, RBBP1, RBP-1, RBBP-1 -ARID4A and Breast Cancer
4
CCL22 16q13 MDC, ABCD-1, SCYA22, STCP-1, DC/B-CK, A-152E5.1 -CCL22 and Breast Cancer
4
MEST 7q32 PEG1 -MEST and Breast Cancer
4
CARS 11p15.4 CARS1, CYSRS, MGC:11246 -CARS and Breast Cancer
4
HTATIP2 11p15.1 CC3, TIP30, SDR44U1 -HTATIP2 and Breast Cancer
4
NOV 8q24.1 CCN3, NOVh, IBP-9, IGFBP9, IGFBP-9 -NOV and Breast Cancer
4
CDK5 7q36 LIS7, PSSALRE -CDK5 and Breast Cancer
4
COL4A2 13q34 ICH, POREN2 -COL4A2 and Breast Cancer
4
PLA2G4A 1q25 PLA2G4, cPLA2-alpha -PLA2G4A and Breast Cancer
4
IRAK2 3p25.3 IRAK-2 -IRAK2 and Breast Cancer
4
CX3CL1 16q13 NTN, NTT, CXC3, CXC3C, SCYD1, ABCD-3, C3Xkine, fractalkine, neurotactin -CX3CL1 and Breast Cancer
4
CASP5 11q22.3 ICH-3, ICEREL-III, ICE(rel)III -CASP5 and Breast Cancer
4
SPRY1 4q28.1 hSPRY1 -SPRY1 and Breast Cancer
4
ARHGDIB 12p12.3 D4, GDIA2, GDID4, LYGDI, Ly-GDI, RAP1GN1, RhoGDI2 -ARHGDIB and Breast Cancer
4
BMPR1B 4q22-q24 ALK6, ALK-6, CDw293 -BMPR1B and Breast Cancer
4
RBP1 3q23 CRBP, RBPC, CRBP1, CRBPI, CRABP-I -RBP1 and Breast Cancer
4
MINA 3q11.2 ROX, MDIG, NO52, MINA53 -MINA and Breast Cancer
4
RAD54L 1p32 HR54, hHR54, RAD54A, hRAD54 -RAD54L and Breast Cancer
4
PRKCDBP 11p15.4 SRBC, HSRBC, CAVIN3, cavin-3 -PRKCDBP and Breast Cancer
4
MCM7 7q21.3-q22.1 MCM2, CDC47, P85MCM, P1CDC47, PNAS146, PPP1R104, P1.1-MCM3 -MCM7 and Breast Cancer
4
MUC16 19p13.2 CA125 -MUC16 and Breast Cancer
4
MIR10A 17q21.32 MIRN10A, mir-10a, miRNA10A, hsa-mir-10a -miR-10a and Breast Cancer
4
SMARCA2 9p22.3 BRM, SNF2, SWI2, hBRM, NCBRS, Sth1p, BAF190, SNF2L2, SNF2LA, hSNF2a -SMARCA2 and Breast Cancer
4
FSCN1 7p22 HSN, SNL, p55, FAN1 -FSCN1 and Breast Cancer
4
SEMA3A 7p12.1 HH16, SemD, COLL1, SEMA1, SEMAD, SEMAL, coll-1, Hsema-I, SEMAIII, Hsema-III -SEMA3A and Breast Cancer
4
PLAGL1 6q24-q25 ZAC, LOT1, ZAC1 -PLAGL1 and Breast Cancer
4
AKAP9 7q21-q22 LQT11, PRKA9, AKAP-9, CG-NAP, YOTIAO, AKAP350, AKAP450, PPP1R45, HYPERION, MU-RMS-40.16A -AKAP9 and Breast Cancer
4
NOX4 11q14.3 KOX, KOX-1, RENOX -NOX4 and Breast Cancer
4
KIAA1524 3q13.13 p90, CIP2A -KIAA1524 and Breast Cancer
4
BCL2L12 19q13.3 -BCL2L12 and Breast Cancer
4
TDGF1 3p21.31 CR, CRGF, CRIPTO -TDGF1 and Breast Cancer
4
SRD5A1 5p15 S5AR 1 -SRD5A1 and Breast Cancer
3
ROCK2 2p24 ROCK-II -ROCK2 and Breast Cancer
3
GPX2 14q24.1 GPRP, GPx-2, GI-GPx, GPRP-2, GPx-GI, GSHPx-2, GSHPX-GI -GPX2 and Breast Cancer
3
ST5 11p15.4 HTS1, p126, DENND2B -ST5 and Breast Cancer
3
MAP3K5 6q22.33 ASK1, MEKK5, MAPKKK5 -MAP3K5 and Breast Cancer
3
MAP2K6 17q24.3 MEK6, MKK6, MAPKK6, PRKMK6, SAPKK3, SAPKK-3 -MAP2K6 and Breast Cancer
3
OCLN 5q13.1 BLCPMG, PPP1R115 -OCLN and Breast Cancer
3
TPM4 19p13.12-p13.11 HEL-S-108 -TPM4 and Breast Cancer
3
CHAT 10q11.2 CMS6, CMS1A, CMS1A2, CHOACTASE -CHAT and Breast Cancer
3
PROX1 1q41 -PROX1 and Breast Cancer
3
MUC3A 7q22 MUC3, MUC-3A -MUC3A and Breast Cancer
3
GATA5 20q13.33 GATAS, bB379O24.1 -GATA5 and Breast Cancer
3
MYH9 22q13.1 MHA, FTNS, EPSTS, BDPLT6, DFNA17, NMMHCA, NMHC-II-A, NMMHC-IIA -MYH9 and Breast Cancer
3
TRIM24 7q32-q34 PTC6, TF1A, TIF1, RNF82, TIF1A, hTIF1, TIF1ALPHA -TRIM24 and Breast Cancer
3
USP7 16p13.3 TEF1, HAUSP -USP7 and Breast Cancer
3
POLB 8p11.2 -POLB and Breast Cancer
3
FLT4 5q35.3 PCL, FLT41, LMPH1A, VEGFR3 -FLT4 and Breast Cancer
3
AGTR2 Xq22-q23 AT2, ATGR2, MRX88 -AGTR2 and Breast Cancer
3
PATZ1 22q12.2 ZSG, MAZR, PATZ, RIAZ, ZBTB19, ZNF278, dJ400N23 -PATZ1 and Breast Cancer
3
SLPI 20q12 ALP, MPI, ALK1, BLPI, HUSI, WAP4, WFDC4, HUSI-I -SLPI and Breast Cancer
3
DGCR8 22q11.2 Gy1, pasha, DGCRK6, C22orf12 -DGCR8 and Breast Cancer
3
JAG2 14q32 HJ2, SER2 -JAG2 and Breast Cancer
3
RAD23B 9q31.2 P58, HR23B, HHR23B -RAD23B and Breast Cancer
3
MBD1 18q21 RFT, PCM1, CXXC3 -MBD1 and Breast Cancer
3
BAGE 21p11.1 not on ref BAGE1, CT2.1 -BAGE and Breast Cancer
3
TNFRSF10D 8p21 DCR2, CD264, TRUNDD, TRAILR4, TRAIL-R4 -TNFRSF10D and Breast Cancer
3
GUSB 7q21.11 BG, MPS7 -GUSB and Breast Cancer
3
HPGD 4q34-q35 PGDH, PGDH1, PHOAR1, 15-PGDH, SDR36C1 -HPGD and Breast Cancer
3
HRK 12q24.22 DP5, HARAKIRI -HRK and Breast Cancer
3
SLC5A8 12q23.1 AIT, SMCT, SMCT1 -SLC5A8 and Breast Cancer
3
SMAD6 15q22.31 AOVD2, MADH6, MADH7, HsT17432 -SMAD6 and Breast Cancer
3
PCM1 8p22-p21.3 PTC4, RET/PCM-1 -PCM1 and Breast Cancer
3
WNT7A 3p25 -WNT7A and Breast Cancer
3
ATF6 1q23.3 ATF6A -ATF6 and Breast Cancer
3
CASP2 7q34-q35 ICH1, NEDD2, CASP-2, NEDD-2, PPP1R57 -CASP2 and Breast Cancer
3
ROCK1 18q11.1 ROCK-I, P160ROCK -ROCK1 and Breast Cancer
3
NKX2-5 5q34 CSX, CSX1, VSD3, CHNG5, HLHS2, NKX2E, NKX2.5, NKX4-1 -NKX2-5 and Breast Cancer
3
BCL2L2 14q11.2-q12 BCLW, BCL-W, PPP1R51, BCL2-L-2 -BCL2L2 and Breast Cancer
3
KCNQ1OT1 11p15.5 LIT1, Kncq1, KvDMR1, KCNQ10T1, KCNQ1-AS2, KvLQT1-AS, NCRNA00012 -KCNQ1OT1 and Breast Cancer
3
CHI3L1 1q32.1 GP39, ASRT7, GP-39, YKL40, CGP-39, YKL-40, YYL-40, HC-gp39, HCGP-3P, hCGP-39 -CHI3L1 and Breast Cancer
3
MSI1 12q24 -MSI1 and Breast Cancer
3
MT1G 16q13 MT1, MT1K -MT1G and Breast Cancer
3
EPHA5 4q13.1 EK7, CEK7, EHK1, HEK7, EHK-1, TYRO4 -EPHA5 and Breast Cancer
3
MT2A 16q13 MT2 -MT2A and Breast Cancer
3
EPB41L3 18p11.32 4.1B, DAL1, DAL-1 -EPB41L3 and Breast Cancer
3
PITX1 5q31.1 BFT, CCF, POTX, PTX1, LBNBG -PITX1 and Breast Cancer
3
MTUS1 8p22 ATBP, ATIP, ICIS, MP44, MTSG1 -MTUS1 and Breast Cancer
3
WWTR1 3q23-q24 TAZ -WWTR1 and Breast Cancer
3
ROR1 1p31.3 NTRKR1, dJ537F10.1 -ROR1 and Breast Cancer
3
MED12 Xq13 OKS, FGS1, HOPA, OPA1, OHDOX, ARC240, CAGH45, MED12S, TNRC11, TRAP230 -MED12 and Breast Cancer
3
LDLR 19p13.2 FH, FHC, LDLCQ2 -LDLR and Breast Cancer
3
PPARGC1A 4p15.1 LEM6, PGC1, PGC1A, PGC-1v, PPARGC1, PGC-1(alpha) -PPARGC1A and Breast Cancer
3
HTRA1 10q26.3 L56, HtrA, ARMD7, ORF480, PRSS11, CARASIL -HTRA1 and Breast Cancer
3
RARRES1 3q25.32 LXNL, TIG1, PERG-1 -RARRES1 and Breast Cancer
3
LAMP1 13q34 LAMPA, CD107a, LGP120 -LAMP1 and Breast Cancer
3
GALM 2p22.1 GLAT, IBD1, BLOCK25, HEL-S-63p -GALM and Breast Cancer
3
WNT5B 12p13.3 -WNT5B and Breast Cancer
3
IL4R 16p12.1-p11.2 CD124, IL4RA, IL-4RA -IL4R and Breast Cancer
3
ANGPT1 8q23.1 AGP1, AGPT, ANG1 -ANGPT1 and Breast Cancer
3
RAD17 5q13 CCYC, R24L, RAD24, HRAD17, RAD17SP -RAD17 and Breast Cancer
3
SERPINC1 1q25.1 AT3, AT3D, ATIII, THPH7 -SERPINC1 and Breast Cancer
3
KAT5 11q13.1 TIP, ESA1, PLIP, TIP60, cPLA2, HTATIP, ZC2HC5, HTATIP1 -KAT5 and Breast Cancer
3
LGALS4 19q13.2 GAL4, L36LBP -LGALS4 and Breast Cancer
3
IL23R 1p31.3 -IL23R and Breast Cancer
3
ESPL1 12q ESP1, SEPA -ESPL1 and Breast Cancer
3
MAGEB2 Xp21.3 DAM6, CT3.2, MAGE-XP-2 -MAGEB2 and Breast Cancer
3
FCGR2A 1q23 CD32, FCG2, FcGR, CD32A, CDw32, FCGR2, IGFR2, FCGR2A1 -FCGR2A and Breast Cancer
3
LIPA 10q23.2-q23.3 LAL, CESD -LIPA and Breast Cancer
3
CRY1 12q23-q24.1 PHLL1 -CRY1 and Breast Cancer
3
NNAT 20q11.2-q12 Peg5 -NNAT and Breast Cancer
3
CXCL11 4q21.2 IP9, H174, IP-9, b-R1, I-TAC, SCYB11, SCYB9B -CXCL11 and Breast Cancer
3
PRKCE 2p21 PKCE, nPKC-epsilon -PRKCE and Breast Cancer
3
UCP2 11q13.4 UCPH, BMIQ4, SLC25A8 -UCP2 and Breast Cancer
3
RABEP1 17p13.2 RAB5EP, RABPT5 -RABEP1 and Breast Cancer
3
CTCFL 20q13.31 CT27, BORIS, CTCF-T, HMGB1L1, dJ579F20.2 -CTCFL and Breast Cancer
3
THY1 11q23.3 CD90, CDw90 -THY1 and Breast Cancer
3
HOXC6 12q13.3 CP25, HOX3, HOX3C, HHO.C8 -HOXC6 and Breast Cancer
3
SMYD3 1q44 KMT3E, ZMYND1, ZNFN3A1, bA74P14.1 -SMYD3 and Breast Cancer
3
MAP3K8 10p11.23 COT, EST, ESTF, TPL2, AURA2, MEKK8, Tpl-2, c-COT -MAP3K8 and Breast Cancer
3
CCNC 6q21 CycC -CCNC and Breast Cancer
3
NOTO 2p13.2 -NOTO and Breast Cancer
3
FOLR1 11q13.4 FBP, FOLR -FOLR1 and Breast Cancer
3
POU2F1 1q24.2 OCT1, OTF1, oct-1B -POU2F1 and Breast Cancer
3
SGK1 6q23 SGK -SGK1 and Breast Cancer
3
SLCO1B3 12p12 LST3, HBLRR, LST-2, OATP8, OATP-8, OATP1B3, SLC21A8, LST-3TM13 -SLCO1B3 and Breast Cancer
3
IL32 16p13.3 NK4, TAIF, TAIFa, TAIFb, TAIFc, TAIFd, IL-32beta, IL-32alpha, IL-32delta, IL-32gamma -IL32 and Breast Cancer
3
BOLL 2q33 BOULE -BOLL and Breast Cancer
3
FER 5q21 TYK3, PPP1R74, p94-Fer -FER and Breast Cancer
3
SOX18 20q13.33 HLTS, HLTRS -SOX18 and Breast Cancer
3
SDC4 20q12 SYND4 -SDC4 and Breast Cancer
3
PPP2R1A 19q13.41 MRD36, PR65A, PP2AAALPHA, PP2A-Aalpha -PPP2R1A and Breast Cancer
3
DEC1 9q32 CTS9 -DEC1 and Breast Cancer
3
MIR34A 1p36.22 mir-34, MIRN34A, mir-34a, miRNA34A -MIR34A and Breast Cancer
3
ENO1 1p36.2 NNE, PPH, MPB1, ENO1L1 -ENO1 and Breast Cancer
3
LRP1B 2q21.2 LRPDIT, LRP-DIT -LRP1B and Breast Cancer
3
MME 3q25.2 NEP, SFE, CD10, CALLA -MME and Breast Cancer
3
CEBPB 20q13.1 TCF5, IL6DBP, NF-IL6, C/EBP-beta -CEBPB and Breast Cancer
3
ZBTB7A 19p13.3 LRF, FBI1, FBI-1, ZBTB7, ZNF857A, pokemon -ZBTB7A and Breast Cancer
3
SERPINB2 18q21.3 PAI, PAI2, PAI-2, PLANH2, HsT1201 -SERPINB2 and Breast Cancer
3
DLEC1 3p21.3 F56, DLC1, CFAP81 -DLEC1 and Breast Cancer
3
CDCP1 3p21.31 CD318, TRASK, SIMA135 -CDCP1 and Breast Cancer
3
IMP3 15q24 BRMS2, MRPS4, C15orf12 -IMP3 and Breast Cancer
3
TLE1 9q21.32 ESG, ESG1, GRG1 -TLE1 and Breast Cancer
3
CTSB 8p22 APPS, CPSB -CTSB and Breast Cancer
3
MIRLET7I 12q14.1 LET7I, let-7i, MIRNLET7I, hsa-let-7i -None and Breast Cancer
3
IRF7 11p15.5 IMD39, IRF7A, IRF7B, IRF7C, IRF7H, IRF-7H -IRF7 and Breast Cancer
3
DLG1 3q29 hdlg, DLGH1, SAP97, SAP-97, dJ1061C18.1.1 -DLG1 and Breast Cancer
3
GADD45B 19p13.3 MYD118, GADD45BETA -GADD45B and Breast Cancer
3
RBM5 3p21.3 G15, H37, RMB5, LUCA15 -RBM5 and Breast Cancer
3
CKS2 9q22 CKSHS2 -CKS2 and Breast Cancer
3
GAS7 17p13.1 MLL/GAS7 -GAS7 and Breast Cancer
2
SOX5 12p12.1 L-SOX5, L-SOX5B, L-SOX5F -SOX5 and Breast Cancer
2
GLIPR1 12q21.2 GLIPR, RTVP1, CRISP7 -GLIPR1 and Breast Cancer
2
C2orf40 2q12.2 ECRG4 -C2orf40 and Breast Cancer
2
PDGFRL 8p22-p21.3 PDGRL, PRLTS -PDGFRL and Breast Cancer
2
CTNND1 11q12.1 CAS, p120, CTNND, P120CAS, P120CTN, p120(CAS), p120(CTN) -CTNND1 and Breast Cancer
2
TP53BP2 1q41 BBP, 53BP2, ASPP2, P53BP2, PPP1R13A -TP53BP2 and Breast Cancer
2
HSP90AA1 14q32.33 EL52, HSPN, LAP2, HSP86, HSPC1, HSPCA, Hsp89, Hsp90, LAP-2, HSP89A, HSP90A, HSP90N, HSPCAL1, HSPCAL4 -HSP90AA1 and Breast Cancer
2
HSD11B1 1q32-q41 HDL, 11-DH, HSD11, HSD11B, HSD11L, CORTRD2, SDR26C1, 11-beta-HSD1 -HSD11B1 and Breast Cancer
2
LIMK1 7q11.23 LIMK, LIMK-1 -LIMK1 and Breast Cancer
2
RASSF6 4q13.3 -RASSF6 and Breast Cancer
2
RNF217-AS1 6q22.33 STL -STL and Breast Cancer
2
USP6 17p13 HRP1, TRE2, TRE17, Tre-2, TRESMCR, USP6-short -USP6 and Breast Cancer
2
MIR10B 2q31.1 MIRN10B, mir-10b, miRNA10B, hsa-mir-10b -MIR10B and Breast Cancer
2
SLC22A18 11p15.4 HET, ITM, BWR1A, IMPT1, TSSC5, ORCTL2, BWSCR1A, SLC22A1L, p45-BWR1A -SLC22A18 and Breast Cancer
2
GALT 9p13 -GALT and Breast Cancer
2
ARF1 1q42 -ARF1 and Breast Cancer
2
IL12B 5q33.3 CLMF, NKSF, CLMF2, IMD28, IMD29, NKSF2, IL-12B -IL12B and Breast Cancer
2
AKAP13 15q24-q25 BRX, LBC, p47, HA-3, Ht31, c-lbc, PRKA13, AKAP-13, AKAP-Lbc, ARHGEF13, PROTO-LB, PROTO-LBC -AKAP13 and Breast Cancer
2
ZNF331 19q13.42 RITA, ZNF361, ZNF463 -ZNF331 and Breast Cancer
2
TM4SF1 3q21-q25 L6, H-L6, M3S1, TAAL6 -TM4SF1 and Breast Cancer
2
GJA1 6q22.31 HSS, CMDR, CX43, EKVP, GJAL, ODDD, AVSD3, HLHS1 -GJA1 and Breast Cancer
2
CTDSPL 3p21.3 PSR1, SCP3, HYA22, RBSP3, C3orf8 -CTDSPL and Breast Cancer
2
MYCBP 1p33-p32.2 AMY-1 -MYCBP and Breast Cancer
2
ACSL3 2q34-q35 ACS3, FACL3, PRO2194 -ACSL3 and Breast Cancer
2
TLR6 4p14 CD286 -TLR6 and Breast Cancer
2
ATP7A Xq21.1 MK, MNK, DSMAX, SMAX3 -ATP7A and Breast Cancer
2
EPHA1 7q34 EPH, EPHT, EPHT1 -EPHA1 and Breast Cancer
2
MGEA5 10q24.1-q24.3 OGA, MEA5, NCOAT -MGEA5 and Breast Cancer
2
TSPO 22q13.31 DBI, IBP, MBR, PBR, PBS, BPBS, BZRP, PKBS, PTBR, mDRC, pk18 -TSPO and Breast Cancer
2
MIR1258 2q31.3 MIRN1258, mir-1258, hsa-mir-1258 -MicroRNA miR-1258 and Breast Cancer
2
FTL 19q13.33 LFTD, NBIA3 -FTL and Breast Cancer
2
TRIM27 6p22 RFP, RNF76 -TRIM27 and Breast Cancer
2
VCAM1 1p32-p31 CD106, INCAM-100 -VCAM1 and Breast Cancer
2
PTPRK 6q22.2-q22.3 R-PTP-kappa -PTPRK and Breast Cancer
2
RAP1GDS1 4q23-q25 GDS1, SmgGDS -RAP1GDS1 and Breast Cancer
2
MAX 14q23 bHLHd4 -MAX and Breast Cancer
2
ODC1 2p25 ODC -ODC1 and Breast Cancer
2
TTL 2q13 -TTL and Breast Cancer
2
CD1D 1q23.1 R3, CD1A -CD1D and Breast Cancer
2
PAWR 12q21 PAR4, Par-4 -PAWR and Breast Cancer
2
CD200 3q13.2 MRC, MOX1, MOX2, OX-2 -CD200 and Breast Cancer
2
LIMD1 3p21.3 -LIMD1 and Breast Cancer
2
GJB2 13q11-q12 HID, KID, PPK, CX26, DFNA3, DFNB1, NSRD1, DFNA3A, DFNB1A -GJB2 and Breast Cancer
2
HAS3 16q22.1 -HAS3 and Breast Cancer
2
ABCB5 7p21.1 ABCB5beta, EST422562, ABCB5alpha -ABCB5 and Breast Cancer
2
PERP 6q24 THW, KCP1, PIGPC1, KRTCAP1, dJ496H19.1 -PERP and Breast Cancer
2
FEZ1 11q24.2 -FEZ1 and Breast Cancer
2
PRDX6 1q25.1 PRX, p29, AOP2, 1-Cys, NSGPx, aiPLA2, HEL-S-128m -PRDX6 and Breast Cancer
2
ELK4 1q32 SAP1 -ELK4 and Breast Cancer
2
IL1RL1 2q12 T1, ST2, DER4, ST2L, ST2V, FIT-1, IL33R -IL1RL1 and Breast Cancer
2
PTPRT 20q12-q13 RPTPrho -PTPRT and Breast Cancer
2
ARHGEF5 7q35 P60, TIM, GEF5, TIM1 -ARHGEF5 and Breast Cancer
1
S100A3 1q21 S100E -S100A3 and Breast Cancer
1
CBLC 19q13.2 CBL-3, RNF57, CBL-SL -CBLC and Breast Cancer
1
SEPT5 22q11.21 H5, CDCREL, PNUTL1, CDCREL1, CDCREL-1, HCDCREL-1 -SEPT5 and Breast Cancer
1
ETV3 1q21-q23 PE1, METS, PE-1, bA110J1.4 -ETV3 and Breast Cancer
1
PLCD1 3p22-p21.3 NDNC3, PLC-III -PLCD1 and Breast Cancer
1
KAT6B 10q22.2 qkf, MORF, MOZ2, GTPTS, MYST4, ZC2HC6B, querkopf -KAT6B and Breast Cancer
1
CRTC3 15q26.1 TORC3, TORC-3 -CRTC3 and Breast Cancer
1
PNN 14q21.1 DRS, DRSP, SDK3, memA -PNN and Breast Cancer
1
COX6C 8q22.2 -COX6C and Breast Cancer
1
EXTL1 1p36.1 EXTL -EXTL1 and Breast Cancer
1
EIF4A2 3q28 DDX2B, EIF4A, EIF4F, BM-010, eIF4A-II, eIF-4A-II -EIF4A2 and Breast Cancer
1
TRG 7p14 TCRG, TRG@ -TRG and Breast Cancer
1
PRTN3 19p13.3 MBN, MBT, NP4, P29, PR3, ACPA, AGP7, NP-4, PR-3, CANCA, C-ANCA -PRTN3 and Breast Cancer
1
ARHGEF12 11q23.3 LARG, PRO2792 -ARHGEF12 and Breast Cancer
1
KMT2D 12q13.12 ALR, KMS, MLL2, MLL4, AAD10, KABUK1, TNRC21, CAGL114 -KMT2D and Breast Cancer
1
GPRC6A 6q22.1 GPCR, bA86F4.3 -GPRC6A and Breast Cancer
1
ERC1 12p13.3 ELKS, Cast2, ERC-1, RAB6IP2 -ERC1 and Breast Cancer
1
SRGAP3 3p25.3 WRP, MEGAP, SRGAP2, ARHGAP14 -SRGAP3 and Breast Cancer
1
ACVRL1 12q13.13 HHT, ALK1, HHT2, ORW2, SKR3, ALK-1, TSR-I, ACVRLK1 -ACVRL1 and Breast Cancer
SMAD7 18q21.1 CRCS3, MADH7, MADH8 -SMAD7 and Breast Cancer
HOXC10 12q13.3 HOX3I Epigenetics
-HOXC10 Silencing in ER positive Breast Cancer
LINC00632 Xq27.1 -RP1-177G6.2 and Breast Cancer
TUBE1 6q21 TUBE, dJ142L7.2 -TUBE1 and Breast Cancer
FSTL3 19p13 FLRG, FSRP -FSTL3 and Breast Cancer

Note: list is not exhaustive. Number of papers are based on searches of PubMed (click on topic title for arbitrary criteria used).

Latest Publications

Zhao M, Ang L, Huang J, Wang J
MicroRNAs regulate the epithelial-mesenchymal transition and influence breast cancer invasion and metastasis.
Tumour Biol. 2017; 39(2):1010428317691682 [PubMed] Related Publications
MicroRNAs are small RNA molecules that play a major role in the post-transcriptional regulation of genes and influence the development, differentiation, proliferation, and apoptosis of cells and the development and progression of tumors. The epithelial-mesenchymal transition is a process by which epithelial cells morphologically transform into cells with a mesenchymal phenotype. The epithelial-mesenchymal transition plays a highly important role in tumor invasion and metastasis. Increasing evidence indicates that microRNAs are tightly associated with epithelial-mesenchymal transition regulation in tumor cells. In breast cancer, various microRNA molecules have been identified as epithelial-mesenchymal transition inducers or inhibitors, which, through different mechanisms and signaling pathways, participate in the regulation of breast cancer invasion and metastasis among various biological behaviors. The epithelial-mesenchymal transition-related microRNAs in breast cancer provide valuable molecules for researching cell invasion and metastasis, and they also provide candidate targets that may be significant for the targeted therapy of breast cancer.

Zhao Y, Yang F, Li W, et al.
miR-29a suppresses MCF-7 cell growth by downregulating tumor necrosis factor receptor 1.
Tumour Biol. 2017; 39(2):1010428317692264 [PubMed] Related Publications
Tumor necrosis factor receptor 1 is the main receptor mediating many tumor necrosis factor-alpha-induced cellular events. Some studies have shown that tumor necrosis factor receptor 1 promotes tumorigenesis by activating nuclear factor-kappa B signaling pathway, while other studies have confirmed that tumor necrosis factor receptor 1 plays an inhibitory role in tumors growth by inducing apoptosis in breast cancer. Therefore, the function of tumor necrosis factor receptor 1 in breast cancer requires clarification. In this study, we first found that tumor necrosis factor receptor 1 was significantly increased in human breast cancer tissues and cell lines, and knockdown of tumor necrosis factor receptor 1 by small interfering RNA inhibited cell proliferation by arresting the cell cycle and inducing apoptosis. In addition, miR-29a was predicted as a regulator of tumor necrosis factor receptor 1 by TargetScan and was shown to be inversely correlated with tumor necrosis factor receptor 1 expression in human breast cancer tissues and cell lines. Luciferase reporter assay further confirmed that miR-29a negatively regulated tumor necrosis factor receptor 1 expression by binding to the 3' untranslated region. In our functional study, miR-29a overexpression remarkably suppressed cell proliferation and colony formation, arrested the cell cycle, and induced apoptosis in MCF-7 cell. Furthermore, in combination with tumor necrosis factor receptor 1 transfection, miR-29a significantly reversed the oncogenic role caused by tumor necrosis factor receptor 1 in MCF-7 cell. In addition, we demonstrated that miR-29a suppressed MCF-7 cell growth by inactivating the nuclear factor-kappa B signaling pathway and by decreasing cyclinD1 and Bcl-2/Bax protein levels. Taken together, our results suggest that miR-29a is an important regulator of tumor necrosis factor receptor 1 expression in breast cancer and functions as a tumor suppressor by targeting tumor necrosis factor receptor 1 to influence the growth of MCF-7 cell.

Moghaddaskho F, Eyvani H, Ghadami M, et al.
Demethylation and alterations in the expression level of the cell cycle-related genes as possible mechanisms in arsenic trioxide-induced cell cycle arrest in human breast cancer cells.
Tumour Biol. 2017; 39(2):1010428317692255 [PubMed] Related Publications
Arsenic trioxide (As2O3) has been used clinically as an anti-tumor agent. Its mechanisms are mostly considered to be the induction of apoptosis and cell cycle arrest. However, the detailed molecular mechanisms of its anti-cancer action through cell cycle arrest are poorly known. Furthermore, As2O3 has been shown to be a potential DNA methylation inhibitor, inducing DNA hypomethylation. We hypothesize that As2O3 may affect the expression of cell cycle regulatory genes by interfering with DNA methylation patterns. To explore this, we examined promoter methylation status of 24 cell cycle genes in breast cancer cell lines and in a normal breast tissue sample by methylation-specific polymerase chain reaction and/or restriction enzyme-based methods. Gene expression level and cell cycle distribution were quantified by real-time polymerase chain reaction and flow cytometric analyses, respectively. Our methylation analysis indicates that only promoters of RBL1 (p107), RASSF1A, and cyclin D2 were aberrantly methylated in studied breast cancer cell lines. As2O3 induced CpG island demethylation in promoter regions of these genes and restores their expression correlated with DNA methyltransferase inhibition. As2O3 also induced alterations in messenger RNA expression of several cell cycle-related genes independent of demethylation. Flow cytometric analysis revealed that the cell cycle arrest induced by As2O3 varied depending on cell lines, MCF-7 at G1 phase and both MDA-MB-231 and MDA-MB-468 cells at G2/M phase. These changes at transcriptional level of the cell cycle genes by the molecular mechanisms dependent and independent of demethylation are likely to represent the mechanisms of cell cycle redistribution in breast cancer cells, in response to As2O3 treatment.

Sato R, Nakano T, Hosonaga M, et al.
RNA Sequencing Analysis Reveals Interactions between Breast Cancer or Melanoma Cells and the Tissue Microenvironment during Brain Metastasis.
Biomed Res Int. 2017; 2017:8032910 [PubMed] Free Access to Full Article Related Publications
Metastasis is the main cause of treatment failure and death in cancer patients. Metastasis of tumor cells to the brain occurs frequently in individuals with breast cancer, non-small cell lung cancer, or melanoma. Despite recent advances in our understanding of the causes and in the treatment of primary tumors, the biological and molecular mechanisms underlying the metastasis of cancer cells to the brain have remained unclear. Metastasizing cancer cells interact with their microenvironment in the brain to establish metastases. We have now developed mouse models of brain metastasis based on intracardiac injection of human breast cancer or melanoma cell lines, and we have performed RNA sequencing analysis to identify genes in mouse brain tissue and the human cancer cells whose expression is associated specifically with metastasis. We found that the expressions of the mouse genes Tph2, Sspo, Ptprq, and Pole as well as those of the human genes CXCR4, PLLP, TNFSF4, VCAM1, SLC8A2, and SLC7A11 were upregulated in brain tissue harboring metastases. Further characterization of such genes that contribute to the establishment of brain metastases may provide a basis for the development of new therapeutic strategies and consequent improvement in the prognosis of cancer patients.

Okada T, Kurabayashi A, Akimitsu N, Furihata M
Expression of Cadherin-17 Promotes Metastasis in a Highly Bone Marrow Metastatic Murine Breast Cancer Model.
Biomed Res Int. 2017; 2017:8494286 [PubMed] Free Access to Full Article Related Publications
We previously established 4T1E/M3 highly bone marrow metastatic mouse breast cancer cells through in vivo selection of 4T1 cells. But while the incidence of bone marrow metastasis of 4T1E/M3 cells was high (~80%) when injected intravenously to mice, it was rather low (~20%) when injected subcutaneously. Therefore, using 4T1E/M3 cells, we carried out further in vitro and in vivo selection steps to establish FP10SC2 cells, which show a very high incidence of metastasis to lungs (100%) and spines (85%) after subcutaneous injection into mice. qRT-PCR and western bolt analysis revealed that cadherin-17 gene and protein expression were higher in FP10SC2 cells than in parental 4T1E/M3 cells. In addition, immunostaining revealed the presence of cadherin-17 at sites of bone marrow and lung metastasis after subcutaneous injection of FP10SC2 cells into mice. Suppressing cadherin-17 expression in FP10SC2 cells using RNAi dramatically decreased the cells' anchorage-independent growth and migration in vitro and their metastasis to lung and bone marrow in vivo. These findings suggest that cadherin-17 plays a crucial role in mediating breast cancer metastasis to bone marrow.

Cheng F, Pan Y, Lu YM, et al.
RNA-Binding Protein Dnd1 Promotes Breast Cancer Apoptosis by Stabilizing the Bim mRNA in a miR-221 Binding Site.
Biomed Res Int. 2017; 2017:9596152 [PubMed] Free Access to Full Article Related Publications
RNA-binding proteins (RBPs) and miRNAs are capable of controlling processes in normal development and cancer. Both of them could determine RNA transcripts fate from synthesis to decay. One such RBP, Dead end (Dnd1), is essential for regulating germ-cell viability and suppresses the germ-cell tumors development, yet how it exerts its functions in breast cancer has remained unresolved. The level of Dnd1 was detected in 21 cancerous tissues paired with neighboring normal tissues by qRT-PCR. We further annotated TCGA (The Cancer Genome Atlas) mRNA expression profiles and found that the expression of Dnd1 and Bim is positively correlated (p = 0.04). Patients with higher Dnd1 expression level had longer overall survival (p = 0.0014) by KM Plotter tool. Dnd1 knockdown in MCF-7 cells decreased Bim expression levels and inhibited apoptosis. While knockdown of Dnd1 promoted the decay of Bim mRNA 3'UTR, the stability of Bim-5'UTR was not affected. In addition, mutation of miR-221-binding site in Bim-3'UTR canceled the effect of Dnd1 on Bim mRNA. Knockdown of Dnd1 in MCF-7 cells confirmed that Dnd1 antagonized miR-221-inhibitory effects on Bim expression. Overall, our findings indicate that Dnd1 facilitates apoptosis by increasing the expression of Bim via its competitive combining with miR-221 in Bim-3'UTR. The new function of Dnd1 may contribute to a vital role in breast cancer development.

Wu HC, Southey MC, Hibshoosh H, et al.
DNA Methylation in Breast Tumor from High-risk Women in the Breast Cancer Family Registry.
Anticancer Res. 2017; 37(2):659-664 [PubMed] Related Publications
To examine DNA methylation profiles in breast tumors of women with a strong breast cancer family history, we measured methylation by bisulfite sequencing in 40 genes in 40 breast tumor tissues from women in the Breast Cancer Family Registry. We selected candidate genes from analysis of the Cancer Genome Atlas project (TCGA) breast data. Compared to TCGA breast cancer, BCFR cases are younger and more likely to be ER-negative. Overall, we found that many of the methylation differences between BCFR tumor and normal adjacent tissues were smaller than that in TCGA samples. We found only 32% of tested genes were hypermethylated in BCFR; the largest difference was 36.1% for SEPW1, and the smallest difference was 10% for RYR2. These data suggest the importance of examining breast cancer cases including familial cases enriched with early-onset cancers to identify methylation markers that can be examined in blood as biomarkers for early detection.

Agosto-Arroyo E, Isayeva T, Wei S, et al.
Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
Cancer Control. 2017; 24(1):102-110 [PubMed] Related Publications
BACKGROUND: The molecular signature of ductal carcinoma in situ (DCIS) in the breast is not well understood. Erb-b2 receptor tyrosine kinase 2 (ERBB2 [formerly known as HER2/neu]) positivity in DCIS is predictive of coexistent early invasive breast carcinoma. The aim of this study is to identify the gene-expression signature profiles of estrogen receptor (ER)/progesterone receptor (PR)-positive, ERBB2, and triple-negative subtypes of DCIS.
METHODS: Based on ER, PR, and ERBB2 status, a total of 18 high nuclear grade DCIS cases with no evidence of invasive breast carcinoma were selected along with 6 non-neoplastic controls. The 3 study groups were defined as ER/PR-positive, ERBB2, and triple-negative subtypes.
RESULTS: A total of 49 genes were differentially expressed in the ERBB2 subtype compared with the ER/PR-positive and triple-negative groups. PROM1 was overexpressed in the ERBB2 subtype compared with ER/PR-positive and triple-negative subtypes. Other genes differentially expressed included TAOK1, AREG, AGR3, PEG10, and MMP9.
CONCLUSIONS: Our study identified unique gene signatures in ERBB2-positive DCIS, which may be associated with the development of invasive breast carcinoma. The results may enhance our understanding of the progression of breast cancer and become the basis for developing new predictive biomarkers and therapeutic targets for DCIS.

Weissenborn C, Ignatov T, Nass N, et al.
GPER Promoter Methylation Controls GPER Expression in Breast Cancer Patients.
Cancer Invest. 2017; 35(2):100-107 [PubMed] Related Publications
Recently, we found that G-protein-coupled estrogen receptor (GPER) protein expression decreased during breast carcinogenesis, and that GPER promoter is methylated. Here we analyzed GPER promoter methylation in 260 primary breast cancer specimens by methylation-specific polymerized chain reaction. The results demonstrated that GPER protein down-regulation significantly correlated with GPER promoter hypermethylation (p < .001). Comparison of 108 tumors and matched normal breast tissues indicated a significant GPER down-regulation in cancer tissues correlating with GPER promoter hypermethylation (p < .001). The latter was an unfavorable factor for overall survival of patients with triple-negative breast cancer (p = .025). Thus GPER promoter hypermethylation might be used as a prognostic factor.

Rezende LM, Marson FA, Lima CS, Bertuzzo CS
Variants of estrogen receptor alpha and beta genes modify the severity of sporadic breast cancer.
Gene. 2017; 608:73-78 [PubMed] Related Publications
INTRODUCTION: Reproductive factors pose a risk for sporadic breast cancer (BC) development owing to the lifetime exposure to estrogen, a hormone responsible for cell proliferation in the breast. Because variants of the estrogen receptor (ER) alpha and beta genes have been associated with BC risk in numerous populations, the objective of the study was to determine whether the risk and severity of sporadic BC was associated with the rs2228480 (ESR1) and rs4986938 (ESR2) variants in a Brazilian population.
METHODS: A total of 253 DNA samples from sporadic BC patients and 257 DNA samples from healthy controls were studied. The samples were genotyped by PCR-RFLP. Epidemiological, clinical, and reproductive factors were analyzed. Statistical tests conducted included the χ(2) test, Fisher's exact test, and Mann-Whitney and Kruskal-Wallis tests or their parametric equivalents.
RESULTS: There was a high frequency of the rs2228480*GG genotype among the ER-positive tumors (OR=2.13; 95% CI=1.189-3.816) and it showed minor association with clinical stage 0 (OR=0.324; 95% CI=0.116-0.904). The rs2228480*GA genotype was associated with minor ER expression, whereas rs2228480*GG was associated with high expression of the progesterone receptor (PR). The frequency of rs4986938*GA was high among women who breastfed (OR=2.11; 95% CI=1.203-3.702), and it showed high association with clinical stage 0 (OR=4.383; 95% CI=1.606-11.96) whereas it had minor association with systemic arterial hypertension (OR=0.53; 95% CI=0.319-0.880). The rs2228480*GG/rs4986938*GG haplotype occurred at a low frequency among women who breastfed (OR=0.525; 95% CI=0.298-0.924) but it was associated with a high expression of PR.
CONCLUSION: The rs2228480 and rs4986938 variants did not alter sporadic BC risk, but they did modulate the BC severity.

Chen JR, Chien HP, Chen KS, et al.
Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer.
Medicine (Baltimore). 2017; 96(2):e5582 [PubMed] Free Access to Full Article Related Publications
BACKGROUND: The prognostic relevance of topoisomerase II alpha (TOP2A) copy number change remains not well established. This study is aimed to investigate the frequency and pattern of TOP2A aberrations; to correlate TOP2A alterations with human epidermal growth factor receptor 2 (HER2) status and clinicopathological parameters, and further to explore prognostic value of TOP2A and HER2 status in breast cancer in Taiwan.
METHODS: We analyzed tissue samples from 311 invasive carcinomas in tissue microarrays for TOP2A and HER2 status by fluorescent in situ hybridization.
RESULTS: TOP2A copy number change is an infrequent genetic event (9.8% amplification and 2.7% deletion) and is present in both HER2-amplified and nonamplified tumors. TOP2A amplification is statistically associated with age >50 at diagnosis (P = 0.016) and HER2 amplification (P < 0.001). HER2 amplification, but not TOP2A amplification, is a predictor of unfavorable prognosis (P = 0.002). Univariate and multivariate analysis showed that higher histologic grading, positive nodal involvement, and HER2 positivity were associated with poorer overall survival. Cytogenetically, double minutes-type amplification is the predominant pattern for both genes (HER2: 64% and TOP2A: 93.1%). Homogeneous staining region-type signals of both genes are resistant to RNase digestion, supporting that these were not nuclear accumulation of mRNA transcripts.
CONCLUSION: Our results demonstrate the prognostic value of tumor grading, nodal involvement, and HER2 status in Taiwanese breast cancer. TOP2A aberrations are an infrequent event independent of HER2 status, and TOP2A amplification carries no prognostic value. The predictive value of TOP2A aberrations in patients of breast cancer taking athracycline-containing treatment in Taiwan remains to be determined in prospectively well-designed clinical trials.

Carvalho MI, Silva-Carvalho R, Pires I, et al.
A Comparative Approach of Tumor-Associated Inflammation in Mammary Cancer between Humans and Dogs.
Biomed Res Int. 2016; 2016:4917387 [PubMed] Free Access to Full Article Related Publications
Infiltrating cells of the immune system are widely accepted to be generic constituents of tumor microenvironment. It has been well established that the development of mammary cancer, both in humans and in dogs, is associated with alterations in numbers and functions of immune cells at the sites of tumor progression. These tumor infiltrating immune cells seem to exhibit exclusive phenotypic and functional characteristics and mammary cancer cells can take advantage of signaling molecules released by them. Cancer related inflammation has an important role in mammary carcinogenesis, contributing to the acquisition of core hallmark capabilities that allow cancer cells to survive, proliferate, and disseminate. Indeed, recent studies in human breast cancer and in canine mammary tumors have identified a growing list of signaling molecules released by inflammatory cells that serve as effectors of their tumor-promoting actions. These include the COX-2, the tumor EGF, the angiogenic VEGF, other proangiogenic factors, and a large variety of chemokines and cytokines that amplify the inflammatory state. This review describes the intertwined signaling pathways shared by T-lymphocytic/macrophage infiltrates and important tissue biomarkers in both human and dog mammary carcinogenesis.

Xue Y, Xu W, Zhao W, et al.
miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4.
Biomed Pharmacother. 2017; 86:426-433 [PubMed] Related Publications
BACKGROUND: MicroRNAs act as posttranscriptional regulators of gene expression in many biological processes, which played a vital role in regulation cancer cells epithelial-to-mesenchymal transition and metastasis. The deregulation of miR-381 has been identified in breast cancer. However, the role and mechanism of miR-381 in breast cancer have not been completely unexplored.
METHODS: Total RNA was extracted from the tissues of 27 patients with breast cancer and two breast cancer cell lines, respectively. The expression levels of miR-381 were examined by quantitative real-time PCR. The stable overexpress or silence miR-381 expression cells lines and control cells line were constructed by lentivirus infection. Subsequently, cell proliferation, cell migration, invasion assay and western blot assay were performed to detect the biological functions of miR-381 in vitro. Moreover, a luciferase reporter assay was conducted to confirm target associations.
RESULTS: In this study, we validated the lower expression of miR-381 in breast cancer tissues than their adjacent non-neoplastic tissues in 27 breast cancer patients. The result also showed that miR-381 was lowly expressed in breast cancer cell lines MCF-7 and MDA-MB-231 than human epithelial cell line MCF-10A. The miR-381 expression was significantly up-regulated under exogenous miRNA-381 treatment in MCF-7 and MDA-MB-231 cells analyzed by quantitative real-time PCR. The results also indicated that an inverse correlation existed between miR-381 expression level and breast cancer cell proliferation, epithelial-to-mesenchymal transition and metastasis. Furthermore, miR-381 was predicted as a regulatory miRNA of CXCR4 in breast cancer, and the data analysis revealed that there was a negatively relationship between miR-381 and CXCR4 expression in breast cancer tissues from the patients. miR-381 played an important role in breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4.
CONCLUSIONS: This present study revealed that miR-381 might be considered as a novel therapeutic target for breast cancer treatment.

Yang X, Du G, Yu Z, et al.
A Novel NHERF1 Mutation in Human Breast Cancer and Effects on Malignant Progression.
Anticancer Res. 2017; 37(1):67-73 [PubMed] Related Publications
Na(+)/H(+) exchanger regulatory factor 1 (NHERF1) has been reported to interact with post-synaptic density protein/Drosophila disc large tumour suppressor/zonula occludens 1 protein (PDZ) binding proteins by its two PDZ domains. These associations have effects on cellular signal transductions. NHERF1 has also been indicated as a cancer-related gene in several solid tumour types. We identified a novel mutation (A190D), of the PDZ2 domain of NHERF1 in breast cancer tissues. NHERF1 A190D mutation abolished NHERF1 modulation of proliferation and migration. In this study, we found that NHERF1 A190D mutation increased nuclear localisation of the protein compared to wild-type NHERF1. It has been reported that YES-associated protein (YAP) interacts with NHERF1. Here we found that NHERF1 A190D mutation increased the binding affinity between NHERF1 and YAP, which inhibited the phosphorylation of YAP. These data suggest that wild-type NHERF1 acts as a tumour suppressor, while NHERF1 A190D mutation abolishes the tumour-suppressive effect in cancer cells, due to A190D mutation-mediated nuclear NHERF1 translocation and induction of YAP phosphorylation.

Pronina IV, Loginov VI, Burdennyy AM, et al.
DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
Gene. 2017; 604:1-8 [PubMed] Related Publications
The methylation of promoter CpG islands and the interaction between microRNAs (miRNAs) and messenger RNAs (mRNAs) of target genes are considered two crucial mechanisms for gene and pathway deregulation in malignant tumors. The aim of this study was to analyze the role of promoter methylation in altering the expression of 13 miRNAs that are associated with breast cancer (BC): miR-124, -125b, -127, -132, -137, -148a, -191, -193a, -203, -212, -34b, -375, -9. The role of methylation in the deregulation of these miRNAs has not been previously assessed in the representative set of BC samples. We used a set of 58 paired (tumor/normal) breast tissue samples and methylation-specific PCR to demonstrate significant aberrations in the methylation patterns of 9 miRNA genes. In particular, we observed hypermethylation of MIR-127, -132, and -193a, and hypomethylation of MIR-191 for the first time. Using quantitative PCR, we established a strong correlation between promoter methylation and expression levels for 12 miRNA genes (all except MIR-212); this finding demonstrates the functional importance of altered methylation patterns. We also performed a correlation analysis between expression levels of the 13 miRNAs and 5 cancer-associated genes, namely RASSF1(A), CHL1, APAF1, DAPK1, and BCL2, which were predicted as targets for these miRNAs, to investigate the impact of these miRNAs on these genes with key cellular functions in BC. Significant negative correlation was revealed for the following miRNA-mRNA pairs: miR-127-5p and DAPK1, miR-375 and RASSF1(A), and miR-124-3p and BCL2. Additionally, we also found a strong association between hypermethylation of MIR-127 and MIR-125b-1 and BC progression, particularly metastasis. Thus, our findings provide evidence for the significant role of methylation in the deregulation of 12 miRNA genes in BC, identify putative novel functional miRNA-mRNA pairs, and suggest MIR-127 and MIR-125b-1 hypermethylation to be potential biomarkers of BC metastasis.

Lee SJ, Kang BW, Kim JG, et al.
AQP5 Variants Affect Tumoral Expression of AQP5 and Survival in Patients with Early Breast Cancer.
Oncology. 2017; 92(3):153-160 [PubMed] Related Publications
BACKGROUND: Our previous study showed the association of AQP5 upregulation with cancer proliferation and migration in breast cancer cell lines and with unfavorable prognosis in patients with early breast cancer (EBC). In the current study, we analyzed the association of AQP5 variants or their haplotypes with AQP5 expression and their prognostic impact for survival in patients with EBC.
METHODS: Three AQP5 polymorphisms (rs74091166, rs3736309, and rs1964676) were selected based on the SNP database and genotyped using the Sequenom MassARRAY in 374 out of 447 patients with EBC in whom AQP5 expression had been investigated in our previous study.
RESULTS: The allele frequencies of the selected variants in the current study were similar to those from Asian data previously reported. In a univariate analysis, both rs74091166 and rs1964676 were statistically associated with survival as a dominant model of minor allele. Moreover, a multivariate survival analysis revealed that the CC genotype of rs1964676 is an independent prognostic marker of survival in EBC patients, regardless of stage, tumor subtype, and adjuvant treatment [hazard ratio = 0.399, 0.384, and 0.205; p = 0.021, 0.027, and 0.016 for disease-free survival (DFS), distant DFS, and disease-specific survival, respectively]. In particular, the CT/TT genotype of rs1964676 showed an association with strong expression of AQP5 (58.6 vs. 26.0%; p = 0.001), without any associations with clinical or pathological characteristics including tumor subtype, stage, or histologic grade.
CONCLUSION: The current study suggests AQP5 rs1964676 as a new potential prognostic marker in patients with EBC involved in AQP5 expression.

Hui L, Geiersbach KB, Downs-Kelly E, Gulbahce HE
RAI1 Alternate Probe Identifies Additional Breast Cancer Cases as Amplified Following Equivocal HER2 Fluorescence In Situ Hybridization Testing: Experience From a National Reference Laboratory.
Arch Pathol Lab Med. 2017; 141(2):274-278 [PubMed] Related Publications
CONTEXT: -In 2013 the American Society of Clinical Oncology and College of American Pathologists updated the HER2 guidelines and changed the equivocal category for HER2 in situ hybridization testing to an average HER2 copy number of 4.0 to 5.9 with a HER2:CEP17 ratio of less than 2.0 and proposed retesting, with an option of using another control probe to avoid false-negative results. RAI1, located at band position 17p11.2, is a popular alternate probe locus for retesting equivocal changes.
OBJECTIVE: -To review experience with the RAI1 alternate probe in HER2 fluorescence in situ hybridization equivocal breast cancers.
DESIGN: -Primary and metastatic breast cancers with equivocal HER2 fluorescence in situ hybridization, retested with an alternate (RAI1) probe, were identified. HER2, RAI1, and CEP17 copy numbers, HER2 to control probe ratios, and genetic heterogeneity were recorded. Hematoxylin-eosin-stained slides were reviewed for type and grade of cancer.
RESULTS: -Of 876 cases tested with CEP17 as the reference probe, 97 (11.1%) had equivocal HER2 fluorescence in situ hybridization results. Additional testing with the RAI1 probe classified 39.2% cases (38 of 97) as amplified with a HER2:RAI1 ratio ranging from 2.0 to 3.2 (mean, 2.37); 3.1% (3 of 97) were still unclassifiable because of a deletion of RAI1.
CONCLUSIONS: -RAI1 identified close to 40% of original HER2 fluorescence in situ hybridization equivocal cases as amplified, making these patients eligible for targeted therapies. It is not known whether guidelines for US Food and Drug Administration-approved probes can be extrapolated to alternate probes when an alternate control probe shows losses or gains. Because of the lack of guidelines for reporting HER2 status with alternate probes, laboratories face challenges in interpreting results.

van Marcke C, De Leener A, Berlière M, et al.
Routine use of gene panel testing in hereditary breast cancer should be performed with caution.
Crit Rev Oncol Hematol. 2016; 108:33-39 [PubMed] Related Publications
Breast cancer is the most frequent cancer occurring in women. Ten percent of these cancers are considered hereditary. Among them, 30% are attributed to germline mutations in the tumor suppressor genes BRCA1 and BRCA2. Other genes of lower penetrance are also known, explaining together up to 40% of the hereditary risk of breast cancer. New techniques, such as next-generation sequencing, allow the simultaneous analysis of multiple genes in a cost-effective way. As a logical consequence, gene panel testing is entering clinical practice with the promise of personalized care. We however advocate that gene panel testing is not ready for non-specialist clinical use, as it generates many variants of unknown significance and includes more genes than are presently considered clinically useful. We hereby review the data for each gene that can change the risk management of patients carrying a pathogenic variant.

Li HC, Chen YF, Feng W, et al.
Loss of the Opa interacting protein 5 inhibits breast cancer proliferation through miR-139-5p/NOTCH1 pathway.
Gene. 2017; 603:1-8 [PubMed] Related Publications
Opa interacting protein 5 (OIP5) has been reported to be over-expressed in several kinds of human cancer. However, the biological function and clinical significance of OIP5 in human breast cancer remains unknown. In this study, we found that OIP5 was notably over-expressed in breast cancer tissues compared with their corresponding nontumorous tissues. Statistical analysis showed a significant correlation of OIP5 expression with advanced clinical stage. Ablation OIP5 inhibited the proliferation of breast cancer cells. OIP5 over-expression inhibited hsa-miR-139-5p expression, antagonized its functions and led to the de-repression of its endogenous target NOTCH1, which was a core oncogene in promoting breast cancer progression. Our results suggested that OIP5 is a potential diagnosis biomarker and therapeutic target for breast cancer.

Zhang HY, Liang F, Wang F, et al.
In Vitro Effects of HAS-2 Gene Silencing on the Proliferation and Apoptosis of the MCF-7 Human Breast Cancer Cell Line.
Cell Physiol Biochem. 2016; 40(3-4):807-817 [PubMed] Related Publications
BACKGROUND: Breast cancer is characterized by a distinct metastatic pattern involving the regional lymph nodes, bone marrow, lung and liver. This study is aimed to investigate the effects of silencing the HAS-2 gene on the proliferation and apoptosis of human breast cancer cells.
METHODS: MCF-7 cells were collected and assigned into control, scrambled siRNA and HAS-2- siRNA groups. After transfection, the morphological changes in the MCF-7 cells were observed using phase contrast microscopy. qRT-PCR and Western blot assays were used to detect the mRNA and protein expression of apoptosis-related proteins. CCK-8 and flow cytometry were performed to evaluate cell proliferation, the cell cycle and apoptosis.
RESULTS: In the control and the scrambled siRNA groups, cells grew adhered to the wall and mainly showed a spindle shape with a clear nucleolus. Compared with the control and scrambled siRNA groups, increases in the number of cells in early apoptosis and metaphase cells in apoptosis were observed in the HAS-2-siRNA group. The HAS-2-siRNA group showed decreased expression of HAS-2 relative to that in the control and scrambled siRNA groups. No significant differences in cell proliferation, cell cycle distribution or apoptosis were noted between the control and scrambled siRNA groups. In the HAS-2-siRNA group, the cell proliferation ability decreased significantly, but the number of cells in the G0/G1 stage, the number of apoptotic cells and the expression of caspase-3 and caspase-9 increased significantly.
CONCLUSION: Our findings indicate that HAS-2 gene silencing may inhibit proliferation and promote apoptosis in the MCF-7 human breast cancer cell line.

Yang F, Luo LJ, Zhang L, et al.
MiR-346 promotes the biological function of breast cancer cells by targeting SRCIN1 and reduces chemosensitivity to docetaxel.
Gene. 2017; 600:21-28 [PubMed] Related Publications
MicroRNAs (miRNAs) are a class of highly conserved small noncoding RNAs that play pivotal roles at the post-transcriptional level in the biological function of various cancers, including breast cancer. In our study, miR-346 mimic, inhibitor, negative control or si-SRCIN1 were transfected into MCF-7 and MCF-7/Doc cells, respectively. Quantitative real time PCR (qRT-PCR) was used to measure miR-346 and SRCIN1 mRNA expressions and western blot was used to detect the expression of SRCIN1 in protein level. CCK-8 and colony formation were employed to verify cell viability and proliferation. Flow cytometry showed the apoptosis. Transwell was performed to detect migration and invasion. The luciferase reporter assay data showed the target correlation of miR-346 and SRCIN1. Firstly, we found that the expression of miR-346 was higher in breast cancer tissues than in their paired corresponding non-cancerous tissues and there was significant inversed correlation between miR-346 and SRCIN1. Overexpression of miR-346 promoted cell proliferation, colony formation, migration and invasion, and reduced apoptosis, sensitivity to Docetaxel (Doc). SRCIN1 was identified as a direct target of miR-346, whose silencing promoted cell proliferation and the IC50 of Doc. Moreover, SRCIN1 silencing reduced the effect of miR-346 down-expression. Taken together, miR-346 may function as an oncogenic miRNA and mediate chemosensitivity to docetaxel through targeting SRCIN1 in breast cancer, targeted modulation of miR-346 expression may became a potential strategy for the treatment.

Azizi Tabesh G, Izadi P, Fereidooni F, et al.
The High Frequency of PIK3CA Mutations in Iranian Breast Cancer Patients.
Cancer Invest. 2017; 35(1):36-42 [PubMed] Related Publications
In breast cancer, somatic mutations of PIK3CA oncogene are common. We investigated the mutational status of exons 9 and 20 of the PIK3CA gene by polymerase chain reaction and direct sequencing in 80 breast tumors, and observed that 45% of these contained PIK3CA mutations in the mentioned exons. These mutations were found more in progesterone receptor positive and Her2- tumors, but this association did not reach a statistically significant level. Also, we observed a significant association between PIK3CA mutations and low-grade tumors. In our study, PIK3CA mutations were related to good and moderate prognosis in breast cancer patients.

Araki K, Ito Y
[A Review Multigene Assays for Clinical Utility in Breast Cancer].
Gan To Kagaku Ryoho. 2016; 43(11):1332-1340 [PubMed] Related Publications
Multigene assays that simultaneously measure the expression of various breast cancer genes have been developed to guide the use of adjuvant chemotherapy in early breast cancer. The efficacy of adjuvant therapies depends on the recurrence risk for an individual patient. As a result, accurate prediction of the recurrence risk is vital for precise adjuvant chemotherapy in individual breast cancer patients. The recurrence risk as typically assessed by conventional examination of histological data of immuno-histological biomarkers(ER, PR, HER2, and Ki-67)is not sufficient to select subsets of patients. Therefore, validated gene expression signatures are useful, in addition to well-established clinico-pathological factors. Available gene expression assay systems, such as MammaPrint®, Oncotype DX®, PAM50 ROR, GGI, EndoPredict®(EP), Breast Cancer IndexSM(BCI), and Curebest®95GC Breast, are recommended. While MammaPrint®and Oncotype DX®are the most predictive of the recurrence risk within the first 5 years of diagnosis, BCI and EPclin have demonstrated utility in predicting late recurrence. In addition, PAM50 provides further biological insights by classifying breast cancers into intrinsic molecular subtypes. These gene expression signatures have become important tools in clinical practice for the identification of low-risk endocrine-positive patients in whom chemotherapy could be avoided. However, there is much work left in the development of a molecular classification considering the biology and novel therapeutic targets in high-risk recurrent disease because chemotherapy has only modest benefits in this population. The recognition of genomic mutations and their relationship to a patient's responsiveness to various therapies will provide important breakthroughs toward precision medicine.

Angus L, Beije N, Jager A, et al.
ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients.
Cancer Treat Rev. 2017; 52:33-40 [PubMed] Related Publications
Mutations in the gene coding for the estrogen receptor (ER), ESR1, have been associated with acquired endocrine resistance in patients with ER-positive metastatic breast cancer (MBC). Functional studies revealed that these ESR1 mutations lead to constitutive activity of the ER, meaning that the receptor is active in absence of its ligand estrogen, conferring resistance against several endocrine agents. While recent clinical studies reported that the occurrence of ESR1 mutations is rare in primary breast cancer tumors, these mutations are more frequently observed in metastatic tissue and circulating cell-free DNA of MBC patients pretreated with endocrine therapy. Given the assumed impact that the presence of ESR1 mutations has on outcome to endocrine therapy, assessing ESR1 mutations in MBC patients is likely to be of significant interest to further individualize treatment for MBC patients. Here, ESR1 mutation detection methods and the most relevant pre-clinical and clinical studies on ESR1 mutations regarding endocrine resistance are reviewed, with particular interest in the ultimate goal of guiding treatment decision-making based on ESR1 mutations.

Tasharrofi B, Soudyab M, Nikpayam E, et al.
Comparative expression analysis of hypoxia-inducible factor-alpha and its natural occurring antisense in breast cancer tissues and adjacent noncancerous tissues.
Cell Biochem Funct. 2016; 34(8):572-578 [PubMed] Related Publications
Hypoxia-inducible factors (HIFs) have been shown to be upregulated in tumor tissues and linked with tumor progression and metastasis in breast cancer. Among regulatory mechanisms for HIF expression is a natural occurring antisense named aHIF, which has been shown to be overexpressed in breast cancer and influence the level of the HIF-1α transcript. In the present study, we analyzed the expression of HIF-1α and aHIF in breast cancer tissues versus adjacent noncancer tissues (ANCTs) in relation with the clinical and biological behavior of the tumors. aHIF has been shown to be expressed in 67.4% of invasive ductal carcinoma samples, while none of ANCTs showed its expression. HIF-1α has been expressed in all of tumors and 90% of ANCTs. Comparison of HIF-1α expression level between tumor and ANCT tissues showed a total upregulation in tumor samples. No statistically significant association has been found between the level of HIF-1α expression in tumor samples and clinicopathologic and demographic characteristics such as age, tumor size, estrogen receptor status, progesterone receptor status, HER2/neu expression level, lymph node status, histological grade, and stage except for a weak correlation between HIF-1α expression and Ki-67 status. Besides, we could not detect any significant correlation between relative expression of HIF-1α and aHIF in tumor samples. Collectively, these data suggest that aHIF overexpression can be used as a potential biomarker in breast cancer. However, further studies are needed for the evaluation of its mechanism of action in regulation of HIF-1α expression in different pathological conditions. HIF-1α overexpression results in the upregulation of several genes that participated in cancer-associated pathways such as proliferation, angiogenesis, and glucose metabolism. We showed that HIF-1α is upregulated in breast tumor samples compared with adjacent noncancerous tissues. Its expression has been associated with Ki-67 status. Its natural occurring antisense is only expressed in tumor tissues. Thus, it can be used as a potential biomarker in breast cancer.

Tsuji D, Ikeda M, Yamamoto K, et al.
Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients: A hospital-based observational study.
Medicine (Baltimore). 2016; 95(44):e5151 [PubMed] Related Publications
Chemotherapy-induced neutropenia (CIN) is one of the major adverse events that necessitate chemotherapy dose reduction. This study aimed to evaluate the association between grade 4 neutropenia and genetic polymorphisms in breast cancer patients. In this genetic polymorphism association study, peripheral blood samples from 100 consecutive breast cancer outpatients, between August 2012 and September 2014, treated with doxorubicin and cyclophosphamide (AC) combination chemotherapy were genotyped for polymorphisms in adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1), cytochrome P450 (CYP) enzyme-coding genes (CYP2B6 and CYP3A5), glutathione S-transferase (GST), and excision repair cross-complementing 1 (ERCC1). Associations between grade 4 neutropenia and genotypes as well as risk factors were examined using multivariate logistic regression. From 100 patients, 32.0% had grade 4 neutropenia. Multivariate logistic regression analysis revealed that ERCC1 118C > T (odds ratio [OR], 3.43; 95% confidence interval [CI], 1.22-9.69; P = 0.020), CYP2B6*6 (OR, 4.51; 95% CI, 1.21-16.95; P = 0.025), body mass index (BMI) (OR, 6.94; 95% CI, 1.15-41.67; P = 0.035), and baseline white blood cell (WBC) count (OR, 2.99; 95% CI, 1.06-8.40; P = 0.038) were significant predictors of grade 4 neutropenia. ERCC1 and CYP2B6 gene polymorphisms were associated with the extent of grade 4 neutropenia in patients receiving AC chemotherapy. In addition to previously known risk factors, BMI and WBC counts, ERCC1 and CYP2B6 gene polymorphisms were also identified as independent strong predictors of grade 4 neutropenia.

Brédart A, Kop JL, De Pauw A, et al.
Effect on perceived control and psychological distress of genetic knowledge in women with breast cancer receiving a BRCA1/2 test result.
Breast. 2017; 31:121-127 [PubMed] Related Publications
Information provision during BRCA1/2 genetic counseling is complex and expected to be increasingly so with gene panel testing. This prospective study evaluated whether genetic knowledge in counselees with breast cancer (BC) after a pre-test genetic counseling visit (T1) enhance their feeling of personal control while minimizing distress after the notification of BRCA1/2 result (T2). At T1, 243 (89% response rate) counselees completed questionnaires on genetic knowledge (BGKQ), perceived cancer genetic risk; of which, at T2, 180 (66%) completed the BGKQ again, scales of anxiety/depression, distress specific to genetic risk, and perceived control. Multilevel models were performed accounting for clinician, and testing an effect of knowledge on psychological outcomes according to the adequacy of counselees' perceived genetic predisposition to cancer. The mean knowledge score was moderate at T1, decreased while not significantly differing by BRCA1/2 test result at T2. Knowledge at T1 had no direct effect on psychological outcomes, but in counselees who over-estimated their cancer genetic risk, higher knowledge at T1 predicted higher specific distress at T2. In BC affected counselees who over-estimate their cancer genetic risk, higher BRCA1/2 pre-test genetic knowledge seem to lead to increased specific distress. Identifying these BC affected counselees who over-estimate their genetic cancer risk and helping them to interpret their genetic knowledge instead of providing them with exhaustive genetic information could minimize their distress after test result receipt.

Liang P, Song Z, Chen D, et al.
GINS2 regulates matrix metallopeptidase 9 expression and cancer stem cell property in human triple negative Breast cancer.
Biomed Pharmacother. 2016; 84:1568-1574 [PubMed] Related Publications
GINS2, a subunit of GINS complex, is critical for the initiation of DNA replication and DNA replication fork progression. The expression of GINS2 is misregulated in many malignant tumors, such as leukemia, breast cancer and melanoma. However, the role of GINS in breast cancer remains poorly characterized. We investigate the possible effect and particular mechanism of GINS in breast cancer cells. We showed that expression of GINS2 is enriched in triple negative breast cancer (TNBC) cell lines. Furthermore, GINS2 knockdown decreased the growth, invasive ability and stem-like property of TNBC cells. Mechanistically, silencing of GINS2 in TNBC cells caused dramatic decrease of matrix metalloproteinase-9 (MMP9). Finally, the abundance of GINS2 correlated with the advance stages of tumor in human TNBC patients. Our studies provided insight into the molecular regulation of TNBC progression and invasion. More importantly, our data suggest that GINS2 could be an outstanding therapeutic target for inhibiting invasive TNBC growth and metastasis.

Zhang Y, Jia H, Wang S, Jiang D
Cumulative review and meta-analyses on the association between MTHFR rs1801133 polymorphism and breast cancer risk: a pooled analysis of 83 studies with 74,019 participants.
Minerva Med. 2017; 108(1):57-73 [PubMed] Related Publications
BACKGROUND: The association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and breast cancer risk has been extensively explored, but their results are conflicting rather than conclusive. To clarify the precise effects of MTHFR polymorphisms on the risk of breast cancer, a systemic review and most comprehensive meta-analysis of all available studies relating MTHFR rs1801133 gene polymorphism to the risk of breast cancer was conducted.
METHODS: Eligible articles were identified by search of databases including Medline (Mainly PubMed), Embase, Web of Science, Chinese Biomedical Literature database (CBM), CNKI and Wanfang Medical databases. Crude ORs with 95% CIs were used to assess the strength of association.
RESULTS: Finally, a total of 83 studies with 35,029 cases and 38,990 controls were included. Overall, MTHFR rs1801133 gene polymorphism was proved to contribute to the risk of breast cancer under all genetic models (TT vs. CC: Pheterogeneity <0.001, OR=1.141, 95%CI=1.065-1.222, P <0.001; TT vs. CT: Pheterogeneity <0.001, OR=1.085, 95%CI=1.021-1.154, P=0.009; TT + CT vs. CC: Pheterogeneity <0.001, OR=1.040, 95%CI=1.020-1.061, P <0.001; TT vs. CC + CT: Pheterogeneity <0.001, OR=1.131, 95%CI=1.052-1.215, P=0.0478; T allele vs. C allele: Pheterogeneity <0.001, OR=1.040, 95%CI=1.009-1.071, P=0.010).
CONCLUSIONS: The results of this meta-analysis suggest that MTHFR rs1801133 gene polymorphism may the therapeutic target for breast cancer.

Wang Y, Zhang X, Chao Z, et al.
MiR-34a modulates ErbB2 in breast cancer.
Cell Biol Int. 2017; 41(1):93-101 [PubMed] Related Publications
Breast cancer is the second highest cause of carcinoma-related death caused by distant metastasis in women. Estrogen receptor (ER), human epidermal growth factor receptor 2, (HER2) and progesterone receptor (PR) are three classified makers of breast cancer, which are defined as ER+, HER2+, and the most serious ER-PR-HER2- (triple-negative). It is well known that ErbB2 (V-Erb-B2 avian erythroblastic leukemia viral oncogene homolog 2) plays an important part in breast cancer. However, the molecular mechanisms underlying ErbB2 action needs to be well studied. In this report, we discovered that the decreased expression levels of miR-34a were inversely correlated with the increased ErbB2 levels in breast cancer. A luciferase reporter assay was done to understand the potential correlation between ErbB2 and miR-34a. Over-expression of miR-34a reduces ErbB2 expression and suppresses breast cancer cell invasion and growth in vitro. What's more, reduced expression of ErbB2 inhibits breast Cancer cell proliferation and re-expression of ErbB2 reversed miR-34a-dependent tumor suppression. Meanwhile, miR-34a levels were correlated inversely with breast cancer malignancy. Our study demonstrates that miR-34a, like ErbB2, might be a diagnostic target in breast cancer.

Disclaimer: This site is for educational purposes only; it can not be used in diagnosis or treatment.

Cite this page: Cotterill SJ. Breast Cancer, Cancer Genetics Web: http://www.cancer-genetics.org/X0401.htm Accessed:

Creative Commons License
This page in Cancer Genetics Web by Simon Cotterill is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Note: content of abstracts copyright of respective publishers - seek permission where appropriate.

 [Home]    Page last revised: 10 March, 2017     Cancer Genetics Web, Established 1999